副甲状腺機能亢進症の外科

出版社： 東京医学社
著者：
発行日： 2016-10-20
分野： 臨床医学：外科  >  外科学一般
ISBN： 9784885632693
電子書籍版： 2016-10-20
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,940 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,940 円(税込)

購入する

目次

  • 副甲状腺機能亢進症の外科

    ―目次―

    第1章　副甲状腺の基礎
    　１．副甲状腺の歴史
    　２．副甲状腺の発生と解剖
    　３．副甲状腺腫大の機序
    　４．副甲状腺の病理組織像

    第2章　副甲状腺機能亢進症
    　１．副甲状腺機能亢進症の定義・概念
    　２．副甲状腺機能亢進症の病因と病態生理
    　３．副甲状腺機能亢進症の臨床
    　４．副甲状腺の画像診断

    第3章　二次性副甲状腺機能亢進症の治療
    　１．内科的治療
    　２．外科的治療の適応
    　３．副甲状腺摘出術（PTx）
    　４．副甲状腺摘出術の利点・欠点
    　５．手術後のさまざまな二次性副甲状腺機能亢進症
    　６．外科治療のトピックス
    　７．外科治療の将来

    第4章　三次性副甲状腺機能亢進症（THPT）の治療
    　１．病態および発症のリスク因子
    　２．内科的治療
    　３．手術適応
    　４．手術術式
    　５．治療効果（内科的治療vs外科的治療も含む）
    　６．THPTに対するPTxの周術期管理のコツと合併症
    　７．THPT治療の今後の展望

    第5章　原発性副甲状腺機能亢進症（PHPT）の治療
    　１．定義，診断
    　２．治療の概要
    　３．術式の選択と実際
    　４．PHPTの内科的治療

    付章　副甲状腺に関する業績
    　英語論文
    　日本語論文

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

はじめに

P.3 掲載の参考文献
1) 高木弘, 冨永芳博 : 腎性上皮小体機能亢進症の外科, 医歯薬出版, 東京, 1993
 
2) 日本透析医学会 : わが国の慢性透析療法の現況 2014年12月31日現在, 2015
 

副甲状腺か上皮小体か

P.4 掲載の参考文献
1) 藤本吉秀, 福光正行 : 上皮小体の臨床, 中外医学社, 東京, 1976
 

第1章 副甲状腺の基礎

P.9 掲載の参考文献
1) Nordenstrom J : The Hunt for the Parathyroids, Wiley-Blackwell, New Jersey, 2012
 
2) Johansson H : History of parathyroid operation and reoperation. Current Controversy in Parathyroid Operation and Reoperation (Akerstrom G eds), pp1-7, RG Landes Company, Austin, 1994
 
3) Johansson H : The Uppsala anatomist Ivar Sandstrom and the parathyroid gland. Usp J Med Sci 120 : 72-77, 2015
 
P.11 掲載の参考文献
1) 溝渕正英, 池田美紗 : 副甲状腺の発生と進化. 腎と骨代謝 26 : 257-261, 2013
 
2) 亀山香織 : 副甲状腺の発生・解剖. 副甲状腺・骨代謝疾患診療マニュアル, 平田結喜緒 (監修), pp8-9, 診断と治療社, 東京, 2013
 
3) Agarwal A, Mishra AK, Lombardi C, et al : Applied embryology of thyroid and parathyroid glands Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd ed), pp15-24, Elsevier, Philadelphia, 2013
 
4) Akerstrom G, Stlberg P : Surgical management of multiglanddular Parathyroid disease Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd ed), pp620-638, Elsevier, Philadelphia, 2013
 
5) 日比八束 : 甲状腺全摘術における副甲状腺同定・温存のtips and pitfalls. 日外会誌 116 : 331-333, 2015
 
P.13 掲載の参考文献
1) Arnold A, Staunton CE, Kim HG, et al : Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 318 : 658-662, 1988
PubMed
2) Arnold A, Kim HG, Gaz RD, et al : Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83 : 2034-2040, 1989
 
3) Arnold A : Genetic basis of endocrine disease 5. Molecular genetics of parathyroid gland neoplasia. J Clin Endocrinol Metab 77 : 1108-1112, 1993
PubMed
4) Tominaga Y, Kohara S, Namii Y, et al : Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20 : 744-750 ; discussion 50-52, 1996
 
5) Imanishi Y, Hosokawa Y, Yoshimoto K, et al : Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107 : 1093-1102, 2001
PubMed
6) Arcidiacono MV, Sato T, Alvarez-Hernandez D, et al : EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 19 : 310-320, 2008
 
7) Fukuda N, Tanaka H, Tominaga Y, et al : Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92 : 1436-1443, 1993
PubMed
8) Brown EM, Gamba G, Riccardi D, et al : Cloning and characterization of an extracellular Ca2+ -sensing receptor from bovine parathyroid. Nature 366 : 575-580, 1993
PubMed
9) Farnebo F, Enberg U, Grimelius L, et al : Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J Clin Endocrinol Metab 82 : 3481-3486, 1997
PubMed
10) Gogusev J, Duchambon P, Hory B, et al : Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51 : 328-336, 1997
PubMed
11) Libutti SK, Crabtree JS, Lorang D, et al : Parathyroid gland-specific deletion of the mouse MEN1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 63 : 8022-8028,2003
PubMed
12) Carpten JD, Robbins CM, Villablanca A, et al : HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32 : 676-680, 2002
PubMed
13) Komaba H, Goto S, Fujii H, et al : Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 : 232-238, 2010
PubMed
14) Shimada T, Mizutani S, Muto T, et al : Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98 : 6500-6505, 2001
PubMed
15) Kuro-o M, Matsumura Y, Aizawa H, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 : 45-51, 1997
PubMed
P.20 掲載の参考文献
1) Dufour DR, Wilkerson SY : The normal parathyroid revisited : percentage of stromal fat. Hum Pathol 13 : 717-721, 1982
PubMed
2) Ordonez NG : Value of GATA3 immunostaining in tumor diagnosis : a review. Adv Anat Pathol 20 : 352-360, 2013
PubMed
3) Johnson SJ : Changing clinicopathological practice in parathyroid disease. Histopathology 56 : 835-851, 2010
PubMed
4) Tominaga Y, Tsuzuki T, Uchida K, et al : Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 55 : 1375-1383, 1999
PubMed
5) Block GA, Martin KJ, de Francisco AL, et al : Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 : 1516-1525, 2004
PubMed
6) Chertow GM, Block GA, Correa-Rotter R, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
7) Sumida K, Nakamura M, Ubara Y, et al : Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. J Clin Pathol 64 : 756-760, 2011
PubMed
8) Tominaga Y, Tsuzuki T, Uchida K, et al : Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 55 : 1375-1383, 1999
PubMed
9) Erickson LA, Jin L, Wollan P, et al : Parathyroid hyperplasia, adenomas, and carcinomas : differential expression of p27Kip1 protein. Am J Surg Pathol 23 : 288-295, 1999
PubMed
10) Hadar T, Shvero J, Yaniv E, et al : Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue. Pathol Oncol Res 11 : 45-49, 2005
PubMed
11) Shi Y, Hogue J, Dixit D, et al : Functional and genetic studies of isolated cells from parathyroid tumors reveal the complex pathogenesis of parathyroid neoplasia. Proc Natl Acad Sci U S A 111 : 3092-3097, 2014
PubMed
12) Mohebati A, Shaha A, Shah J : Parathyroid carcinoma : challenges in diagnosis and treatment. Hematol Oncol Clin North Am 26 : 1221-1238, 2012
PubMed
13) Shattuck TM, Valimaki S, Obara T, et al : Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349 : 1722-1729, 2003
PubMed
14) Schantz A, Castleman B : Parathyroid carcinoma. A study of 70 cases. Cancer 31 : 600-605, 1973
PubMed
15) Truran PP, Johnson SJ, Bliss RD, et al : Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1 : using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg 38 : 2845-2854, 2014
PubMed
16) Agarwal A, Pradhan R, Kumari N, et al : Molecular Characteristics of Large Parathyroid Adenomas. World J Surg 40 : 607-614, 2016
PubMed
17) Tominaga Y, Tsuzuki T, Matsuoka S, et al : Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg 32 : 815-821, 2008
PubMed
18) Padgett SN, Walsh SN, Santa Cruz DJ : Parathyroid hyperplasia of auto-transplanted tissue in forearm skin. J Cutan Pathol 38 : 232-235, 2011
PubMed
19) Osamura RY, Hunt JL : Current practices in performing frozen sections for thyroid and parathyroid pathology. Virchows Arch 453 : 433-440, 2008
PubMed
20) Geelhoed GW, Silverberg SG : Intraoperative imprints for the identification of parathyroid tissue. Surgery 96 : 1124-1131, 1984
PubMed
21) Westra WH, Pritchett DD, Udelsman R : Intraoperative confirmation of parathyroid tissue during parathyroid exploration : a retrospective evaluation of the frozen section. Am J Surg Pathol 22 : 538-544, 1998
PubMed

第2章 副甲状腺機能亢進症

P.22 掲載の参考文献
1) 近藤剛史, 遠藤逸郎, 松本俊夫 : 副甲状腺関連疾患 内科から. 副甲状腺・骨代謝疾患診療マニュアル, 平田結喜緒監修, pp26-29, 診断と治療社, 東京, 2013
 
2) Saunders BD, Saunders EF, Gauger PG : Lithium therapy and hyperparathyroidism : an evidence-based assessment. World J Surg 33 : 2314-2323, 2009
PubMed
P.26 掲載の参考文献
1) Razzaque MS : The FGF23-Klotho axis : endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5 : 611-619, 2009
PubMed
2) Cha SK, Ortega B, Kurosu H, et al : Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA 105 : 9805-9810, 2008
PubMed
3) Christakos S, Ajibade DV, Dhawan P, et al : Vitamin D : metabolism. Rheum Dis Clin North Am 38 : 1-11, 2012
PubMed
4) Slatopolsky E, Finch J, Denda M, et al : Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97 : 2534-2540, 1996
PubMed
5) Hu MC, Shi M, Zhang J, et al : Klotho : a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24 : 3438-3450, 2010
PubMed
6) Meir T, Durlacher K, Pan Z, et al : Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int 86 : 1106-1115, 2014
PubMed
7) Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al : The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 : 4003-4008, 2007
PubMed
8) Farrow EG, White KE : Recent advances in renal phosphate handling. Nat Rev Nephrol 6 : 207-217, 2010
PubMed
9) Kumar R, Thompson JR : The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 22 : 216-224, 2011
PubMed
10) Naveh-Many T, Bell O, Silver J, et al : Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate. FEBS Lett 529 : 60-64, 2002
PubMed
11) Lopez MF, Rezai T, Sarracino DA, et al : Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 56 : 281-290, 2010
PubMed
12) Kawata T, Imanishi Y, Kobayashi K, et al : Direct in vitro evidence of extracellular Ca2+ -induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells. J Clin Endocrinol Metab 90 : 5774-5778, 2005
 
13) ADHR Consortium : Autosomal dominant hypophosphataemic rickets in associated with mutations in FGF23. Nat Genet 26 : 345-348, 2000
PubMed
14) Jonsson KB, Zahradnik R, Larsson T, et al : Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348 : 1656-1663, 2003
 
15) Urakawa I, Yamazaki Y, Shimada T, et al : Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 : 770-774, 2006
PubMed
16) Kuro-o M, Matsumura Y, Aizawa H, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 : 45-51, 1997
PubMed
17) Kurosu H, Yamamoto M, Clark JD, et al : Suppression of aging in mice by the hormone Klotho. Science 309 : 1829-1833, 2005
PubMed
18) Imanishi Y, et al : Cinacalcet HCl suppresses cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperthyroidism. Calcif Tissue Int 89 : 29-35, 2011
 
19) Egbuna OI, Brown EM : Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 22 : 129-148, 2008
PubMed
20) Dvorak MM, Chen TH, Orwoll B, et al : Constitutive activity of the osteoblast Ca2+ -sensing receptor promotes loss of cancellous bone. Endocrinology 148 : 3156-3163, 2007
 
21) Arnlov J, Carlsson AC, Sundstrom J, et al : Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 83 : 160-166, 2013
PubMed
22) McGregor R, Li G, Penny H, et al : Vitamin D in renal transplantation-from biological mechanisms to clinical benefits. Am J Transplant 14 : 1259-1270, 2014
PubMed
P.30 掲載の参考文献
1) Bricker NS, Slatopolsky E, Reiss E, et al : Calcium, phosphorus and bone in renal disease and transplantation. Arch Intern Med 123 : 543-553, 1969
PubMed
2) Massry SG, Coburn JW, Lee DB, et al : Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 78 : 357-364, 1973
PubMed
3) Tanaka Y, Deluca HF : The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 154 : 566-574, 1973
PubMed
4) Nakano C, Hamano T, Fujii N, et al : Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7 : 810-819, 2012
PubMed
5) Gutierrez O, Isakova T, Rhee E, et al : Fibroblast growth factor-23 mitigates hyperphophatemia but accentuates calcitoriol deficiency in chronic kidney disease. J Am Soc Nephrol 16 : 2205-2215, 2005
 
6) Tominaga Y, Tanaka Y, Sato K, et al : Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13 : 78-86, 1997
PubMed
7) Cunningham J, Locatelli F, Rodriguez M : Secondary hyperparathyroidism : pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6 : 913-921, 2011
PubMed
8) Komaba H, Goto S, Fujii H, et al : Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 : 232-238, 2010
PubMed
9) Galitzer H, Ben-Dov IZ, Silver J, et al : Parathyroid cell resintance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77 : 211-218, 2010
PubMed
P.34 掲載の参考文献
1) Matsuoka S, Tominaga Y, Uno N, et al : Calciphylaxis : a rare complication of patients who required parathyroidectomy for advanced renal hyperparathyroidism. World J Surg 29 : 632-635, 2005
PubMed
P.36 掲載の参考文献
1) Berson SA, Yalow RS : Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab 28 : 1037-1047, 1968
PubMed
2) Torres PU : The need for reliable serum parathyroid hormone measurements. Kidney Int 70 : 240-243, 2006
PubMed
3) Gao P, Scheibel S, D'Amour P, et al : Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84 : implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16 : 605-614, 2001
PubMed
4) John MR, Goodman WG, Gao P, et al : A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments : implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84 : 4287-4290, 1999
 
5) Slatopolsky E, Finch J, Clay P, et al : A novel mechanism for skeletal resistance in uremia. Kidney Int 58 : 753-761, 2000
 
6) Komaba H, Goto S, Fukagawa M : Critical issues of PTH assays in CKD. Bone 44 : 666-670, 2009
PubMed
7) Souberbielle JC, Boutten A, Carlier MC, et al : Inter-method variability in PTH measurement : implication for the care of CKD patients. Kidney Int 70 : 345-350, 2006
PubMed
8) Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al : Evaluation of Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally invasive parathyroidectomy. Langenbecks Arch Surg 394 : 843-849, 2009
PubMed
9) Hiramitsu T, Tominaga Y, Okada M, et al : A retrospective study of the impact of intraoperative intact parathyroid hormone monitoring during total parathyroidectomy for secondary hyperparathyroidism : STARD study. Medicine 94 : e1213, 2015
 
P.39 掲載の参考文献
1) Kuro-o M, Matsumura Y, Aizawa H, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 : 45-51, 1997
PubMed
2) Isakova T, Wahl P, Vargas GS, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 : 1370-1378, 2011
 
3) Wang H, Yoshiko Y, Yamamoto R, et al : Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23 : 939-948, 2008
PubMed
4) Maier GS, Horas K, Kurth AA, et al : Prevalence of vitamin D deficiency in patients with bone metastases and multiple myeloma. Anticancer Res 35 : 6281-6285, 2015
PubMed
5) Kutmon M, Coort SL, de Nooijer K, et al : Integrative network-based analysis of mRNA and microRNA expression in 1,25-dihydroxyvitamin D3-treated can cer cells. Genes Nutr 10 : 484, 2015
 
6) Chonchol M, Greene T, Zhang Y, et al : Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study. J Am Soc Nephrol 27 : 227-237, 2016
PubMed
7) Girgis CM, Clifton-Bligh RJ, Hamrick MW, et al : The roles of vitamin D in skeletal muscle : form, function, and metabolism. Endocr Rev 34 : 33-83, 2013
PubMed
8) Marie PJ, Glorieux FH : Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcif Tissue Int 35 : 443-448, 1983
PubMed
9) Yuan Q, Sato T, Densmore M, et al : Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/- mice. PLoS Genet 8 : e1002726, 2012
PubMed
10) Yajima A, Pasch A, Nitta K : Efficacy and safety of cinacalcet in chronic kidney disease stage III and IV. Clinical Medicine : Therapeutics 1 : 1661-1666, 2009
 
11) Tominaga Y : Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl. Clin Calcium 19 : 545-550, 2009
 
12) Tominaga Y, Uchida K, Haba T, et al : More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 38 (4 Suppl 1) : S168-S171, 2001
 
13) Moe SM, Abdalla S, Chertow GM, et al : Effects of cinacalcet on fracture events in patients receiving hemodialysis : The EVOLVE Trial. J Am Soc Nephrol 26 : 1466-1475, 2015
 
14) Lam NN, Triliana R, Sawyer RK, et al : Vitamin D receptor overexpression in osteoblasts and osteocytes prevents bone loss during vitamin D-deficiency. J Steroid Biochem Mol Biol 144 Pt A : 128-131, 2014
 
15) Rudser KD, de Boer IH, Dooley A, et al : Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18 : 2401-2407, 2007
PubMed
16) Abdelhadi M, Nordenstrom J : Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 83 : 3845-3851, 1998
PubMed
17) London GM, Marchais SJ, Guerin AP, et al : Ankle-brachial index and bone turnover in patients on dialysis. J Am Soc Nephrol 26 : 476-483, 2015
PubMed
18) Block GA, Kilpatrick RD, Lowe KA, et al : CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 8 : 2132-2140, 2013
PubMed
19) Danese MD, Kim J, Doan QV, et al : PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47 : 149-156, 2006
PubMed
20) Yajima A, Inaba M, Tominaga Y, et al : Increased osteocytre death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism. J Bone Miner Res 25 : 2374-2381, 2010
PubMed
21) Yajima A, Ogawa Y, Takahashi HE, et al : Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 42 : 729-738, 2003
PubMed
22) Yajima A, Inaba M, Tominaga Y, et al : Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 74 : 775-781, 2008
PubMed
23) Yajima A, Inaba M, Ogawa Y, et al : Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol Dial Transplant 22 : 1645-1657, 2007
PubMed
24) Shiizaki K, Hatamura I, Negi S, et al : Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism. Kidney Int 70 : 486-495, 2006
PubMed
25) Schober HC, Han ZH, Foldes AJ, et al : Mineralized bone loss at different sites in dialysis patients : implications for prevention. J Am Soc Nephrol 9 : 1225-1233, 1998
PubMed
26) Yajima A, Inaba M, Tominaga Y, et al : Minimodeling reduces the rate of cortical bone loss in patients with secondary hyperparathyroidism. Am J Kidney Dis 49 : 440-451, 2007
PubMed
27) Tatsumi S, Ishii K, Amizuka N, et al : Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5 : 464-475, 2007
PubMed
28) Morse A, McDonald MM, Kelly NH, et al : Mechanical load increases in bone formation via a sclerostin-independent pathway. J Bone Miner Res 29 : 2456-2467, 2014
 
29) Qiu S, Rao RD, Palnitkar S, et al : Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res 18 : 1657-1663, 2003
 
30) Kondoh S, Inoue K, Igarashi K, et al : Estrogen receptor α in osteocytes regulates trabecular bone formation in female mice. Bone 60 : 68-77, 2014
 
31) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113 : S1-S130, 2009
PubMed
32) Dallas SL, Prideaux M, Bonewald LF : The osteocyte : an endocrine cell... and more. Endocr Rev 34 : 658-690, 2013
PubMed
P.52 掲載の参考文献
1) Miller DL : Pre-operative localization and interventional treatment of parathyroid tumors : when and how? World J Surg 15 : 706-715, 1991
PubMed
2) 高木弘, 冨永芳博 : 上皮小体の画像診断. 腎性上皮小体機能亢進症の外科, pp51-64, 医歯薬出版, 東京, 1993
 
3) Aspinall SR, Nicholson S, Bliss RD, et al : The impact of surgeon-based ultrasonography for parathyroid disease on a British endocrine surgical practice. Ann R Coll Surg Engl 94 : 17-22, 2012
PubMed
4) 鈴木眞一 : 副甲状腺CT・MRI検査. 内分泌外科の要点と盲点, 幕内雅敏 (監修), pp221-223, 文光堂, 東京, 2012
 
5) 荒木力 : MRIの基礎知識. MRIのABC, 片山仁 (監修), pp29-51, 日本医師会, 東京, 1999
 
6) Ferlin G, Borsato N, Camerani M, et al : New perspectives in localizing enlarged parathyroids by technetium-thallium subtraction scan. J Nucl Med 24 : 438-441, 1983
PubMed
7) Taillefer R, Boucher Y, Potvin C, et al : Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double phase study). J Nucl Med 33 : 1801-1807, 1992
PubMed
8) Coakley AJ, Kettle AG, Wells CP, et al : 99mTc sestamibi-a new agent for parathyroid imaging. Nucl Med Commun 10 : 791-794, 1989
PubMed
9) Crane P, Laliberte R, Heminway S, et al : Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 20 : 20-25, 1993
PubMed
10) Carpentier A, Jeannotte S, Verreault J, et al : Preoperative localization of parathyroid lesions in hyperparathyroidism : relationship between technetium-99m-MIBI uptake and oxyphil cell content. J Nucl Med 39 : 1441-1444, 1998
 
11) 日下部きよ子 : 副甲状腺シンチグラフィ. 最新臨床核医学改訂第3版, 久田欣一 (監修), pp362-370, 金原出版, 東京, 1999
 
12) Carty SE, Norton JA : Management of patients with persistent or recurrent primary hyperparathyroidism. World J Surg 15 : 716-723, 1991
PubMed
13) 榎本拓茂, 林京子, 梶田咲美乃, 他 : 原発性副甲状腺機能亢進症の術式選択における術中迅速病理診断の有用性. 日外科系連会誌 31 : 1-6, 2006
 
14) Mitmaker EJ, Grogan RH, Duh QY : Guide to Preoperative Parathyroid Localization Testing. Surgery of the Thyroid and Parathyroid Glands, 2nd ed, pp539-545, Saunders, Philadelphia, 2013
 
15) 来住野修 : 副甲状腺 (上皮小体). 頸部エコーのスクリーニングとステップアップガイド, 来住野修, 高梨昇 (編), pp60-70, 医歯薬出版, 東京, 2015
 
16) 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006
 
17) Matsuoka S, Tominaga Y, Sato T, et al : Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism. Ther Apher Dial 12 : 391-395, 2008
PubMed
18) Randall GJ, Zald PB, Cohen JI, et al : Contrast-enhanced MDCT characteristics of parathyroid adenomas. Am J Roentgenol 193 : W139-W143, 2009
 
19) 日下部きよ子, 大島統男, 高見博, 他 : 過機能性副甲状腺結節の検出における99mTc-MIBI シンチグラフィの臨床的有用性-第III相多施設臨床試験報告-. 核医 35 : 887-899, 1998
Medical*Online
20) 中駄邦博, 高田尚幸, 高橋弘昌 : 副甲状腺の画像診断の進歩 MIBIシンチグラフィ, CTを中心に. 日内分泌・甲状腺外会誌 29 : 176-182, 2012
 
21) 岡本友好, 他 : 原発性上皮小体機能亢進症における術前部位診断. 共済医報 38 : 265-270, 1989
 
22) 沖原宏治, 斎藤雅人, 内田睦, 他 : 原発性副甲状腺機能亢進症の局在診断各種画像診断法の診断能. 泌外 7 : 143-147, 1994
 
23) 家根旦有, 江本美枝, 岡本英之, 他 : MIBIシンチによる原発性副甲状腺機能亢進症の局在診断. 頭頸部腫瘍 29 : 186-190, 2003
 
24) 安松隆治, 大蔵謙治, 山本智矢 : 原発性副甲状腺機能亢進症症例の臨床的検討. 耳鼻と臨床 53 : 144-147, 2007
 
25) 山村博, 南汐里, 高橋知子, 他 : 副甲状腺機能亢進症に対する腫大腺検出能の検討. 超音波検技 40 : 213, 2015
Medical*Online

第3章 二次性副甲状腺機能亢進症の治療

P.57 掲載の参考文献
1) Gutierrez OM : Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease : updating the "trade-off" hypothesis. Clin J Am Soc Nephrol 5 : 1710-1716, 2010
PubMed
2) Barsotti G, Cupisti A, Morelli E, et al : Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation. Nephron 79 : 137-141, 1998
PubMed
3) Aparicio M, Lafage MH, Combe C, et al : Low-protein diet and renal osteodystrophy. Nephron 58 : 250-252, 1991
PubMed
4) Barsotti G, Morelli E, Guiducci A, et al : Reversal of hyperparathyroidism in severe uremics following very low-protein and low-phosphorus diet. Nephron 30 : 310-313, 1982
PubMed
5) D'Alessandro C, Piccoli GB, Cupisti A : The "phosphorus pyramid" : a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol 16 : 9, 2015
PubMed
6) Cupisti A, Kalantar-Zadeh K : Management of natural and added dietary phosphorus burden in kidney disease. Semin Nephrol 33 : 180-190, 2013
PubMed
7) Hodsman AB, Steer BM : Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining. J Am Soc Nephrol 2 : 1318-1327, 1992
 
8) Petit TL : Aluminum in human dementia. Am J Kidney Dis 6 : 313-316, 1985
PubMed
9) Akizawa T, Kinugasa E, Akiba T, et al : Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int Suppl 62 : S72-S74, 1997
PubMed
10) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
11) Steenbock H : The induction of growth promoting and calcifying properties in a ration by exposure to light. Science 60 : 224-225, 1924
 
12) Gray R, Boyle I, DeLuca HF : Vitamin D metabolism : the role of kidney tissue. Science 172 : 1232-1234, 1971
 
13) Tominaga Y, Kohara S, Namii Y, et al : Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20 : 744-750, 1996
PubMed
14) Slatopolsky E, Weerts C, Thielan J, et al : Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74 : 2136-2143, 1984
PubMed
15) Tsukamoto Y, Nomura M, Takahashi Y, et al : The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 57 : 23-28, 1991
PubMed
16) Komaba H, Nakanishi S, Fujimori A, et al : Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 5 : 2305-2314, 2010
 
17) Raggi P, Chertow GM, Torres PU, et al ; ADVANCE Study Group : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011
 
P.63 掲載の参考文献
1) Moe S, Drueke T, Cunningham J, et al : Kidney Disease : Improving Global Outcomes (KDIGO) : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
2) Fukagawa M, Yokoyama K, Koiwa F, et al ; CKD-MBD Guideline Working Group ; Japanese Society for Dialysis Therapy : Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17 : 247-288, 2013
 
3) Lei XG, Porres JM : Phytase enzymology, applications, and biotechnology. Biotechnol Lett 25 : 1787-1794, 2003
PubMed
4) Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al : Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 5 : 519-530, 2010
PubMed
5) Noori N, Kalantar-Zadeh K, Kovesdy CP, et al : Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Clin J Am Soc Nephrol 5 : 683-692, 2010
PubMed
6) Jamal SA, Vandermeer B, Raggi P, et al : Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease : an updated systematic review and meta-analysis. Lancet 382 : 1268-1277, 2013
PubMed
7) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
8) Raggi P, Chertow GM, Torres PU, et al ; ADVANCE Study Group : The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011
 
9) EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, et al : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
10) Wheeler DC, London GM, Parfrey PS, et al ; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators : Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis : the EValuation Of Cinacalcet HCl Therapy to Lower Cardio Vascular Events (EVOLVE) trial. J Am Heart Assoc 3 : e001363, 2014
 
11) 松浦有希子, 稲熊大城, 板脇大輔, 他 : 透析液カルシウム濃度3.0 mEq/L から2.75 mEq/L への変更は血清PTH濃度に影響しない. 透析会誌 45 : 873-880, 2012
 
12) Dusso AS : Kidney disease and vitamin D levels : 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney Int Suppl 1 : 136-141, 2011
PubMed
13) Andress DL : Vitamin D in chronic kidney disease : a systemic role for selective vitamin D receptor activation. Kidney Int 69 : 33-43, 2006
PubMed
14) Melamed ML, Thadhani RI : Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 7 : 358-365, 2012
PubMed
15) Gunta SS, Thadhani RI, Mak RH : The effect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol 9 : 337-347, 2013
PubMed
16) Querfeld U, Mak RH : Vitamin D deficiency and toxicity in chronic kidney disease : in search of the therapeutic window. Pediatr Nephrol 25 : 2413-2430, 2010
PubMed
17) Faul C, Amaral AP, Oskouei B, et al : FGF23 induces left ventricular hypertrophy. J Clin Invest 121 : 4393-4408, 2011
PubMed
18) Wolf M : Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82 : 737-747, 2012
PubMed
P.68 掲載の参考文献
1) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006
 
2) Tominaga Y, Numano M, Tanaka Y, et al : Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13 : 87-96, 1997
PubMed
3) Gogusev J, Duchambon P, Hory B, et al : Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51 : 328-336, 1997
PubMed
4) Fukuda N, Tanaka H, Tominaga Y, et al : Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92 : 1436-1443, 1993
PubMed
5) Fukagawa M, Kitaoka M, Inazawa T, et al : Imaging of the parathyroid in chronic renal failure : diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens 6 : 349-355, 1997
PubMed
6) Tominaga Y, Matsuoka S, Uno N : Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis. World J Surg 33 : 2335-2342, 2009
PubMed
7) Kitaoka M, Fukagawa M, Kurokawa K : Direct injections of calcitriol into enlarged parathyroid glands in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1 : 563-567, 1995
 
8) Shiizaki K, Hatamura I, Negi S, et al : Highly concentrated calcitriol and its analogues induce apoptosis of parathyroid cells and regression of the hyperplastic gland-study in rats. Nephrol Dial Transplant 23 : 1529-1536, 2008
PubMed
9) Tanaka M, Itoh K, Matsushita K, et al : Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium × phosphorus product in secondary hyperparathyroidism. Nephron Clin Pract 102 : c1-c7, 2006
 
10) Tanaka M, Itoh K, Matsushita K, et al : Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines. Ther Apher Dial 9 : 48-52, 2005
 
P.72 掲載の参考文献
1) 冨永芳博 : Cinacalcet HCl導入前後のSHPTに対するPTxの変遷. 腎と透析 15 別冊腎不全外科 : 6-15, 2015
 
2) 冨永芳博 : 副甲状腺CKD-MBD腫大の治療法をどう選択するか? CKD-MBDガイドライン. 臨透析28 : 954-960, 2012
 
3) Tentori F, Wang M, Bieber BA, et al : Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis : the DOPPS study. Clin J Am Soc Nephrol 10 : 98-109, 2015
PubMed
4) Tominaga Y, Matsuoka S, Uno N, et al : Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 12 (Suppl 1) : S21-S26, 2008
 
5) Tominaga Y, Sato K, Numano M, et al : Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 44 (Suppl 1) : S42-S47, 1995
 
6) Tominaga Y, Tanaka Y, Sato K, et al : Histopathology, pathophysiology and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13 : 78-86, 1997
PubMed
7) Fukuda N, Tanaka H, Tominaga Y, et al : Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92 : 1436-1443, 1993
PubMed
8) Gogusev J, Duchambon P, Hory B, et al : Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51 : 328-336, 1997
PubMed
9) Tominaga Y, Kohara S, Namii Y, et al : Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20 : 744-750, 1996
PubMed
10) Tominaga Y, Tsuzuki T, Uchida K, et al : Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 55 : 1375-1383, 1999
PubMed
11) Tominaga Y, Tanaka Y, Sato K, et al : Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World J Surg 16 : 595-603, 1992
PubMed
12) Komaba H, Goto S, Fujii H, et al : Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 : 232-238, 2010
PubMed
13) Fukagawa M, Kitaoka M, Yi H, et al : Serial evaluation of parathyroid size by ultrasonography is another useful marker for long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 68 : 221-228, 1994
PubMed
14) Tominaga Y, Inaguma D, Matsuoka S, et al : Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 10 : 198-204, 2006
PubMed
15) Matsuoka S, Tominaga Y, Sato T, et al : Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism. Ther Apher Dial 12 : 391-395, 2008
PubMed
16) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
17) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidner Int 76 (Suppl 113) : 1-140, 2009
 
P.78 掲載の参考文献
1) 冨永芳博 : 二次性副甲状腺機能亢進症に対する副甲状腺摘出術3000例の経験. 日透析医会誌 29 : 92-97, 2014
 
2) Malberti F, Marcelli D, Conte F, et al : Parathyroidectomy in patients on renal replacement therapy : an epidemiologic study. J Am Soc Nephrol 12 : 1242-1248, 2001
 
3) Young EW, Albert JM, Satayathum S, et al : Predictors and consequences of altered mineral metabolism : the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 : 1179-1187, 2005
 
4) Tentori F, Wang M, Bieber BA, et al : Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperpara thyroidism on chronic hemodialysis : the DOPPS study. Clin J Am Soc Nephrol 10 : 98-109, 2015
 
5) Tominaga Y, Kakuta T, Yasunaga C, et al : Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the Parathyroid Surgeons' Society of Japan. Ther Apher Dial 20 : 6-11, 2016
PubMed
6) Foley RN, Li S, Liu J, et al : The fall and rise of parathyroidectomy in U. S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 16 : 210-218, 2005
 
7) Schneider R, Kolios G, Koch BM, et al : An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism-the German perspective. Surgery 148 : 1091-1099, 2010
PubMed
P.86 掲載の参考文献
1) Parfrey PS, Foley RN, Harnett JD, et al : Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11 : 1277-1285, 1996
PubMed
2) 一ノ宮大雅, 福崎誠 : ベンゾジアゼピンによる麻酔導入 : ミダゾラムで患者にとって快適な麻酔を. LiSA 14 : 972-976, 2007
 
3) 片山浩 : 血液透析を受けている. 麻酔科トラブルシューティングA to Z, 高崎眞弓ほか (編), pp148-151, 文光堂, 東京, 2010
 
4) Costantino TG, et al : Ultrasonography-guided peripheral intravenous access versus traditional approaches in patients with difficult intravenous access. Ann Emerg Med 46 : 456-461, 2005
PubMed
5) 山蔭道明 : レミフェンタニルを併用したセボフルラン麻酔. LiSA 14 : 858-862, 2007
 
6) Reed AP, Yudkowitz FS : Case 28 parathyroidectomy. Clinical cases in anesthesia, 4th ed, pp134-136, Saunders, Philadelphia, 2014
 
7) Roger A, et al, 新見能成 (監訳) : 弁疾患の麻酔管理. 心臓手術の麻酔, 第3版, pp345-379, メディカル・サイエンス・インターナショナル, 東京, 2009
 
P.88 掲載の参考文献
1) Iwamoto N, Sato N, Nishida M, et al : Total parathyroidectomy improves survival of hemodialysis patients with secondary hyperparathyroidism. J Nephrol 25 : 755-763, 2012
PubMed
2) Iwamoto N, Sato N, Nishida M, et al : Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients. Clin Exp Nephrol, 2015 Dec 17 [Epub ahead of print]
 
3) Rothmund M, Wagner PK, Schark C : Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism : a randomized trial. World J Surg 15 : 745-750, 1991
PubMed
4) Hampl H, Steinmuller T, Frohling P, et al : Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab 25 : 161-170, 1999
PubMed
5) Takagi H, Tominaga Y, Uchida K, et al : Subtotal versus total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 200 : 18-23, 1984
PubMed
6) Tominaga Y, Uchida K, Haba T, et al : More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 38 (Supple) : S168-S171, 2001
 
7) Yu I, DeVita MV, Komisar A : Long-term follow-up after subtotal parathyroidectomy in patients with renal failure. Laryngoscope 108 : 1824-1828, 1998
PubMed
8) Hargrove GM, Pasieka JL, Hanley DA, et al : Short-and long-term outcome of total parathyroidectomy with immediate autografting versus subtotal parathyroidectomy in patients with end-stage renal disease. Am J Nephrol 19 : 559-564, 1999
 
9) Wells SA Jr, Gunnells JC, Shelburne JD, et al : Transplantation of the parathyroid glands in man : clinical indications and results. Surgery 78 : 34-44, 1975
PubMed
P.94 掲載の参考文献
1) 冨永芳博, 松岡慎 : 腎性副甲状腺機能亢進症に対する副甲状腺全摘・自家移植術 手術のtips and pitfalls. 日外会誌 110 : 96-100, 2009
 
2) 冨永芳博 : 副甲状腺 (上皮小体) 摘出術のコツと注意点. 手術 60 別冊 : 1959-1964, 2006
 
3) Tominaga Y : Surgical treatment of secondary and tertiary hyperparathyroidism. Surgery of Thyroid and Parathyroid Glands, 2nd ed (Rundolph GW ed), pp639-647, Elsevier, Philadelphia, 2012
 
P.102 掲載の参考文献
1) Pasieka JL, Parsons LL : A prospective surgical outcome study assessing the impact of parathyroidectomy on symptoms in patients with secondary and tertiary hyperparathyroidism. Surgery 128 : 531-539, 2000
PubMed
2) Chou FF, Chen JB, Lee CH, et al : Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Arch Surg 136 : 1064-1068, 2001
PubMed
3) Yajima A, Ogawa Y, Takahashi HE, et al : Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 42 : 729-738, 2003
PubMed
4) Yajima A, Inaba M, Tominaga Y, et al : Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 74 : 775-781, 2008
PubMed
5) Rudser KD, de Boer IH, Dooley A, et al : Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18 : 2401-2407, 2007
PubMed
6) Goto N, Tominaga Y, Matsuoka S, et al : Cardiovascular complications caused advanced secondary hyperparathyroidism in chronic dialysis patients ; specifical focus on dilated cardiomyopathy. Clin Exp nephrol 9 : 138-141, 2005
 
7) Goicoechea M, Gomez-Campdera F, Polo JR, et al : Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin : effect of parathyroidectomy. Clin Nephrol 45 : 420-421, 1996
PubMed
8) Chou FF, Lee CH, Lee CT : Muscle force and bone mineral density after parathyroidectomy and subcutaneous autotransplantation for secondary hyperparathyroidism. World J Surg 23 : 452-457, 1999
PubMed
9) Yasunaga C, Nakamoto M, Matsuo K, et al : Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. Am J Surg 178 : 332-336, 1999
PubMed
10) Chou FF, Chen JB, Hsieh KC, et al : Cognitive changes after parathyroidectomy in patients with secondary hyperparathyroidism. Surgery 143 : 526-532, 2008
PubMed
11) Goldsmith DJ, Covic AA, Venning MC, et al : Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism : further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 27 : 819-825, 1996
PubMed
12) Pizzarelli F, Fabrizi F, Postorino M, et al : Parathyroidectomy and blood pressure in hemodialysis patients. Nephron 63 : 384-389, 1993
PubMed
13) Tanaka Y, Funahashi H, Imai T, et al : Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism. Semin Surg Oncol 13 : 125-133, 1997
PubMed
14) Tominaga Y : Current status of parathyroidectomy for secondary hyperparathyroidism in Japan. Nephrol Dial Transplant Plus 1 (Suppl) : iii35-iii38, 2008
 
15) Mazzaferro S, Pasquali M, Farcomeni A, et al : Parathyroidectomy as therapeutic tool for targeting the recommended NKF-K/DOQITM ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant 23 : 2319-2323, 2008
 
16) Duffy A, Schurr M, Warner T, et al : Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol 13 : 96-102, 2006
PubMed
17) Patetsios P, Bernstein M, Kim S, et al : Severe necrotizing mastopathy caused by calciphylaxis alleviated by total parathyroidectomy. Am Surg 66 : 1056-1058, 2000
PubMed
18) Di Leo C, Gallieni M, Bestetti A, et al : Cardiac and pulmonary calcification in a hemodialysis patient : partial regression 4 years after parathyroidectomy. Clin Nephrol 59 : 59-63, 2003
 
19) Kestenbaum B, Andress DL, Schwartz SM, et al : Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66 : 2010-2016, 2004
PubMed
20) Trombetti A, Stoermann C, Robert JH, et al : Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World J Surg 31 : 1014-1021, 2007
PubMed
21) Costa-Hong V, Jorgetti V, Gowdak LH, et al : Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 142 : 699-703, 2007
PubMed
22) Ishani A, Liu J, Wetmore JB, et al : Clinical outcomes after parathyroidectomy in a national wide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 10 : 90-97, 2015
 
23) Komaba H, Taniguchi M, Wada A, et al : Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88 : 350-359, 2015
PubMed
24) Iwamoto N, Sato N, Nishida M, et al : Total parathyroidectomy improves survival of hemodialysis patients with secondary hyperparathyroidism. J Nephrol 25 : 755-763, 2012
PubMed
25) The EVOLVE Trial investigators : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 : 2482-2494, 2012
PubMed
26) Narayan R, Perkins RM, Berbano EP, et al : Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD : a cost utility analysis. Am J Kidney Dis 49 : 801-813, 2007
PubMed
27) Schneider R, Kolios G, Koch BM, et al : An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism-the German perspective. Surgery 148 : 1091-1099, 2010
PubMed
28) 山本貴之, 冨永芳博 : 透析患者の悪性腫瘍の危険因子と予防対策 甲状腺がんの早期発見. 臨牀透析 31 : 53-57, 2015
 
P.105 掲載の参考文献
1) 冨永芳博 : 術後上皮小体機能検査, 移植上皮小体機能. 腎性上皮小体機能亢進症の外科, pp104-109, 医歯薬出版, 東京, 1993
 
2) Niederle B, Roka R, Brennan MF : The transplantation of parathyroid tissue in man : development indications, technique, and results. Endocr Rev 3 : 245, 1982
PubMed
3) Tentori F, Wang M, Bieber BA, et al : Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis : the DOPPS study. Clin J Am Soc Nephrol 10 : 98-109, 2015
PubMed
P.108 掲載の参考文献
1) Tominaga Y, Matsuoka S, Uno N, et al : Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients. World J Surg 34 : 1312-1317, 2010
PubMed
2) de Francisco AL, Amado JA, Casanova D, et al : Recurrence of hyperparathyroidism after total parathyroidectomy with autotransplantation : a new technique to localize the source of hormone excess. Nephron 58 : 306-309, 1991
PubMed
3) Tominaga Y, Tanaka Y, Sato K, et al : Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World J Surg 16 : 595-603, 1992
PubMed
P.109 掲載の参考文献
1) Tominaga Y : Surgical treatment of secondary and tertiary hyperparathyroidism. Surgery of Thyroid and Parathyroid Glands, 2nd ed (Rudolph GW ed), pp639-647, Elsevier, Philadelphia, 2012
 
P.118 掲載の参考文献
1) Numano M, Tominaga Y, Uchida K, et al : Surgical significance of supernumerary parathyroid glands in renal hyperparathyroidism. World J Surg 22 : 1098-1103, 1998
PubMed
2) Pattou FN, Pellissier LC, Noel C, et al : Supernumerary parathyroid glands : frequency and surgical significance in treatment of renal hyperparathyroidism. World J Surg 24 : 1330-1334, 2000
PubMed
3) Akerstrom G, Malmaeus J, Bergstrom R : Surgical anatomy of human parathyroid glands. Surgery 95 : 14-21, 1984
PubMed
4) Uno N, Tominaga Y, Matsuoka S, et al : Incidence of parathyroid glands located in thymus in patients with renal hyperparathyroidism. World J Surg 32 : 2516-2519, 2008
PubMed
5) Gilmour JR : The gross anatomy of the parathyroid glands. J Pathol 46 : 133-149, 1938
 
6) Norris EH : The parathyroid glands and lateral thyroid in man : their morphogenesis, histogenesis, topographic anatomy and prenatal growth. Contrib Embryol Carnegie Inst Wash 26 : 247-294, 1937
 
7) Edis AJ, Purnell DC, van Heerden JA : The undescended "parathymus". Ann Surg 190 : 64-68, 1979
PubMed
8) Billingsley KG, Fraker DL, Doppman JL, et al : Localization and operative management of undescended parathyroid adenomas in patients with persistent primary hyperparathyroidism. Surgery 116 : 982-990, 1994
PubMed
9) 登政和 : 上皮小体の外科解剖. 外科診療 29 : 147-155, 1987
 
10) Wang C : The anatomic basis of parathyroid surgery. Ann Surg 183 : 271-275, 1976
PubMed
11) 田中浩史, 長坂隆治, 波井康, 他 : 腎性上皮機能亢進症における上皮小体下降不全について. 腎と透析 40 別冊腎不全外科 1996 : 168, 1996
 
12) 泉純子, 和田祐和, 岡本譲二, 他 : 下降不全副甲状腺による持続性腎性副甲状腺機能亢進症の2例. 内分泌外科 15 : 195-199, 1998
 
13) Matsuoka S, Tominaga Y, Uno N, et al : Surgical significance of undescended parathyroid gland in renal hyperparathyroidism. Surgery 139 : 815-820, 2006
PubMed
14) Yamashiro N, Tominaga Y, Matsuoka S, et al : A supernumerary parathyroid gland located in an unusual site, parapharyngeal space, in a patient with persistent renal hyperparathyroidism. Nephrol Dial Transplant 23 : 419-420, 2008
 
P.121 掲載の参考文献
1) Matsuoka S, Tominaga Y, Sato T, et al : Recurrent renal hyperparathyroidism caused by parathyromatosis. World J Surg 31 : 299-305, 2007
PubMed
2) Eriguchi R, Umakoshi J, Tominaga Y, et al : Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCL. Nephrol Dial Transplant Plus 4 : 218-220, 2008
 
P.125 掲載の参考文献
1) 亀山香織 : 病理学から. 平田結喜緒 (監修) : 副甲状腺・骨代謝疾患診療マニュアル, pp34-35, 診断と治療社, 東京, 2015
 
2) Janice L, Pasieka, Rafael O, et al : Parathyroid Carcinoma. Surgery of the Thyroid and Parathyroid Glands, Second Ed (Gregory W. Randolph), Elsevier, pp665-672, 2012
 
3) Tominaga Y, Tsuzuki T, Matsuoka S, et al : Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg 32 : 815-821, 2008
PubMed
P.127 掲載の参考文献
1) Kovacs KA, Gay JD : Remission of primary hyperparathyroidism due to spontaneous infarction of a parathyroid adenoma. Case report and review of the literature. Medicine (Baltimore) 77 : 398-402, 1998
PubMed
2) Kozlow W, Demeure MJ, Welniak LM, et al : Acute extracapsular parathyroid hemorrhage : case report and review of the literature. Endocr Pract 7 : 32-36, 2001
PubMed
P.129 掲載の参考文献
1) Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al : Evaluation of Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally invasive parathyroidectomy. Langenbecks Arch Surg 394 : 843-849, 2009
PubMed
2) Hiramitsu T, Tominaga Y, Okada M, et al : A retrospective study of the impact of intraoperative intact parathyroid hormone monitoring during total parathyroidectomy for secondary hyperparathyroidism STARD Study. Medicine 94 : e1213, 2015
 
3) Uno N, Tominaga Y, Matsuoka S, et al : Incidence of parathyroid glands located in thymus in patients with renal hyperparathyroidism. World J Surg 32 : 2516-2519, 2008
PubMed
4) Akerstrom G, Malmaeus J, Bergstrom R : Surgical anatomy of human parathyroid glands. Surgery 95 : 14-21, 1985
 
5) Wang C : The anatomic basis of parathyroid surgery. Ann Surg 183 : 271-275, 1976
PubMed
P.132 掲載の参考文献
1) Randolph GW : Surgical anatomy of the recurrent laryngeal nerve. Surgery of the Thyroid and Parathyroid Glands (Randolph GW ed), pp300-342, Elsevier Science, Philadelphia, 2002
 
2) Masuoka H, Miyauchi A, Higashiyama T, et al : Prospective randomized study on injury of the external branch of the superior laryngeal nerve during thyroidectomy comparing intraoperative nerve monitoring and a conventional technique. Head Neck 37 : 1456-1460, 2015
 
3) Chan WF, Lang BH, Lo CY : The role of intraoperative neuromonitoring of recurrent laryngeal nerve during thyroidectomy : A comparative study on 1000 nerves at risk. Surgery 140 : 866-872, 2006
PubMed
P.135 掲載の参考文献
1) 熊谷厚志, 片山宏, 他 : 切開・縫合用機器とその使い方. 外科治療 102 : 9-16, 2010
 
2) Owaki T, Nakano S, Arimura K, et al : The ultrasonic coagulating and cutting system injuries nerve function. Endoscopy 34 : 575-579, 2002
PubMed
3) Progorel`ic Z, Perko Z, Druzijanic N, et al : How to prevent lateral thermal damage to tissue using the harmonic scalpel : experimental study on pig small intestine and abdominal wall. Eur Surg Res 43 : 235-240, 2009
 
4) 宮章博, 宮内昭 : 甲状腺外科手術におけるLiga-Sure Small Jawの有用性. 日本内分泌外会誌 30 : 193-196, 2013
 
5) 平池修, 大須賀穣, 他 : 近年の手術関連機器の進歩. 産婦の実際 63 : 1-7, 2014
 
P.137 掲載の参考文献
1) 日本透析医学会 : わが国の慢性透析療法の現況2014年12月31日現在, 2015
 
2) Malberti F, Marcelli D, Conte F, et al : Parathyroidectomy in patients on renal replacement therapy : an epidemiologic study. J Am Soc Nephrol 12 : 1242-1248, 2001
 
3) Tentori F, Wang M, Bieber BA, et al : Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis : the DOPPS study. Clin J Am Soc Nephrol 10 : 98-109, 2015
PubMed
4) Tominaga Y, Kakuta T, Yasunaga C, et al : Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the Parathyroid Surgeons' Society of Japan. Ther Apher Dial 20 : 6-11, 2016
PubMed
5) Sumida K, Nakamura M, Ubara Y, et al : Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. J Clin Pathol 64 : 756-760, 2011
PubMed
6) 山下弘幸 : 原発性副甲状腺機能亢進症の臨床-症例に学ぶ, 2014
 

第4章 三次性副甲状腺機能亢進症 ( THPT ) の治療

P.143 掲載の参考文献
1) Tominaga Y : Surgical and medical management of tertiary hyperparathyroidism. World J Endo Surg 2 : 105-109, 2010
 
2) Taniguchi M, Tokumoto M, Matsuo D, et al : Persistent hyperparathyroidism in renal allograft recipients : vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int 70 : 363-370, 2006
PubMed
3) 日本透析医学会ワーキンググループ : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
4) Yamamoto T, Tominaga Y, Okada M, et al : Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg 40 : 600-606, 2016
PubMed
P.145 掲載の参考文献
1) Gwinner W, Suppa S, Mengel M, et al : Early calcification of renal allografts detected by protocol biopsies : causes and clinical implications. Am J Transplant 5 : 1934-1941, 2005
PubMed
2) Ambuhl PM, Meier D, Wolf B, et al : Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation : impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 34 : 875-883, 1999
PubMed
3) Palmer SC, Strippoll GF, McGregor DO : Interventions for preventing bone disease in kidney transplant recipients : a systematic review of randomized controlled trials. Am J Kidney Dis 45 : 638-649, 2005
 
4) Rodd C : Bisphosphonates in dialysis and transplantation patients : efficacy and safety tissues. Perit Dial Int 21 (Suppl 3) : S256-S260, 2001
 
5) Jansson S, Morgan E : Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism. World J Surg 28 : 1293-1297, 2004
PubMed
6) El-agroudy AE, El-Husseini AA, El-Sayed M, et al : A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 67 : 2039-2045, 2005
 
7) De Sevaux RG, Hoitsma AJ, Corstens FH, et al : Treatment with vitamin D and calcium reduces bone loss after renal transplantation : a randomized study. J Am Soc Nephrol 13 : 1608-1614, 2002
PubMed
8) Torres A, Garcia S, Gomez A, et al : Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 65 : 705-712, 2004
 
9) Josephson MA, Schumm LP, Chiu MY, et al : Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 78 : 1233-1236, 2004
PubMed
10) 矢野彰三, 杉本利嗣 : 原発性副甲状腺機能亢進症とシナカルセト塩酸塩. 腎と骨代謝 21 : 139-145, 2008
 
11) Cohen JB, Gordon CE, Balk EM, et al : Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients : a systematic review and meta-analysis. Transplantation 94 : 1041-1048, 2012
PubMed
12) 山本貴之, 冨永芳博, 他 : 腎移植後遷延性副甲状腺機能亢進症に対する副甲状腺全摘前腕筋肉内自家移植術の意義. 日臨腎移植会誌 2 : 180-183, 2014
 
P.148 掲載の参考文献
1) Triponez F, Clark OH, Vanrenthergem Y, et al : Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg 248 : 18-30, 2008
PubMed
2) Park JH, Kang SW, Jeong JJ, et al : Surgical treatment of tertiary hyperparathyroidism after renal transplantation : a 31-year experience in a single institution. Endocr J 58 : 827-833, 2011
 
3) Taniguchi M, Tokumoto M, Matsuo D, et al : Persistent hyperparathyroidism in renal allograft recipients : vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int 70 : 363-370, 2006
PubMed
4) Giangrande A, Castiglioni A, Solbiati L, et al : Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 7 : 412-421, 1992
PubMed
5) Gwinner W, Suppa S, Mengel M, et al : Early calcification of renal allografts detected by protocol biopsies : causes and clinical implications. Am J Transplant 5 : 1934-1941, 2005
PubMed
6) Yamamoto T, Tominaga Y, Okada M, et al : Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg 40 : 600-606, 2016
PubMed
P.151 掲載の参考文献
1) Schlosser K, Endres N, Celik I, et al : Surgical treatment of tertiary hyperparathyroidism : the choice of procedure matters! World J Surg 31 : 1947-1953, 2007
PubMed
2) Hsieh TM, Sun CK, Chen YT, et al : Total parathyroidectomy versus subtotal parathyroidectomy in the treatment of tertiary hyperparathyroidism. Am Surg 78 : 600-606, 2012
PubMed
3) Park JH, Kang SW, Jeong JJ, et al : Surgical treatment of tertiary hyperparathyroidism after renal transplantation : a 31-year experience in a single institution. Endocr J 58 : 827-833, 2011
 
4) Yamamoto T, Tominaga Y, Okada M, et al : Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg 40 : 600-606, 2016
PubMed
P.153 掲載の参考文献
1) Yang RL, Freeman K, Reinke CE, et al : Tertiary hyperparathyroidism in kidney transplant recipients : characteristics of patients selected for different treatment strategies. Transplantation 94 : 70-76, 2012
PubMed
2) Yamamoto T, Tominaga Y, Okada M, et al : Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg 40 : 600-606, 2016
PubMed
3) Tominaga Y : Surgical and medical management of tertiary hyperparathyroidism. World J Endocr Surg 2 : 105-109, 2010
 
4) Pihlstrom H, Dahle DO, Mjoen G, et al : Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation 99 : 351-359, 2015
PubMed
P.155 掲載の参考文献
1) Triponez F, Clark OH, Vanrenthergem Y, et al : Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg 248 : 18-30, 2008
PubMed
2) Massfelder T, Parekh N, et al : Effect of intrarenally infused parathyroid hormone-related peptide- (1-34) in humans. J Clin Endocrinol Metab 82 : 2548-2551, 1996
 
3) Schwarz A, Rustien G, Merkel S, et al : Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 22 : 584-591, 2007
PubMed
4) Yamamoto T, Tominaga Y, Okada M, et al : Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg 40 : 600-606, 2016
PubMed
5) Park JH, Kang SW, Jeong JJ, et al : Surgical treatment of tertiary hyperparathyroidism after renal transplantation : a 31-year experience in a single institution. Endocr J 58 : 827-833, 2011
 

第5章 原発性副甲状腺機能亢進症 ( PHPT ) の治療

P.162 掲載の参考文献
1) 近藤剛史, 遠藤逸郎, 松本俊夫 : 副甲状腺関連疾患 内科から. 副甲状腺・骨代謝疾患診療マニュアル, 平田結喜緒監修, pp26-29, 診断と治療社, 東京, 2013
 
2) 千葉優子 : 高カルシウム血症の鑑別診断. 副甲状腺・骨代謝疾患診療マニュアル, 平田結喜緒監修, pp44-45, 診断と治療社, 東京, 2013
 
3) 山内美香, 杉本利嗣 : 原発性副甲状腺機能亢進症病態・診断. 副甲状腺・骨代謝疾患診療マニュアル, 平田結喜緒監修, pp48-51, 診断と治療社, 東京, 2013
 
4) Wang TS, Yen TWF, Evans DB : Parathyroid management in the MEN syndromes. Surgery of the Thyroid and Parathyroid Gland (Randolf GW 2nd eds), pp605-612, Elsevier, Philadelphia, 2013
 
5) Randolf GW, Grant CS, Kamani D : Princeples in surgical management of primary hyperparathyroidism. Surgery of the Thyroid and Parathyroid Gland (Randolf GW 2nd eds), pp546-566, Elsevier, Philadelphia, 2013
 
6) Silverberg SJ, Bilezikian JP : Primary hyperparathyroidism : pathophysiology, surgical indications, and preoperative workup. Surgery of the Thyroid and Parathyroid Gland (Randolf GW 2nd eds), pp531-538, Elsevier, Philadelphia, 2013
 
7) 多発性内分泌腫瘍症診療ガイドブック編集委員会編 : 多発性内分泌腫瘍症診療ガイドブック, 金原出版, 東京, 2013
 
P.166 掲載の参考文献
1) Randolf GW, Grant CS, Kamani D : Princeples in surgical management of primary hyperparathyroidism. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp546-566, Elsevier, Philadelphia, 2013
 
2) Siperstein AE, Stephne AE, Milas M : Standard bilateral parathyroid exploration. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp567-579, Elsevier, Philadelphia, 2013
 
3) Perrier ND, Parangi S : Minimally invasive single gland exploration. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp580-589, Elsevier, Philadelphia, 2013
 
4) Pawell AC Libutti ST : Reoperation for sporadic primary hyperparathyroidism. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp657-664, Elsevier, Philadelphia, 2013
 
5) Mitmaker EJ, Grogan RH, Yang DUH : Guide to preoperative parathyroid localization testing. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp605-612, Elsevier, Philadelphia, 2013
 
6) 竹内靖博 : 原発性副甲状腺機能亢進症治療の適応と内科的治療. 副甲状腺・骨代謝疾患診療マニュアル, 平田結喜緒監修, pp52-56, 診断と治療社, 東京, 2013
 
7) Bilezikian JP, Brandi ML, Eastell R, et al : Guidelines for the management of asmptomatic primary hyperparathyroidism : summary statement from the fourth international workshop. J Clin Endocrinol Metab 99 : 3561-3569, 2014
 
8) Carneiro-PLA D, Pellitteri PK : Intraoperative PTH monitoring parathyroid surgery. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp605-612, Elsevier, Philadelphia, 2013
 
P.168 掲載の参考文献
1) Randolf GW, Grant CS, Kamani D : Princeples in surgical management of primary hyperparathyroidism. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp546-566, Elsevier, Philadelphia, 2013
 
2) Siperstein AE, Stephne AE, Milas M : Standard bilateral parathyroid exploration. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp567-579, Elsevier, Philadelphia, 2013
 
3) Perrier ND, Parangi S : Minimally invasive single gland exploration. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp580-589, Elsevier, Philadelphia, 2013
 
4) Akerstrom G, Stlberg P : Surgical management of multiglandular parathyroid disease. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp620-638, Elsevier, Philadelphia, 2013
 
5) Pawell AC, Libutti ST : Reoperation for sporadic primary hyperparathyroidism. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp657-664, Elsevier, Philadelphia, 2013
 
6) Pasieka JL, Toro Serra RO, Clayman G, et al : Parathyroid carcinoma. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp605-612, Elsevier, Philadelphia, 2013
 
7) 亀山香織 : 病理学から. 平田結喜緒 (監修), 副甲状腺・骨代謝疾患診療マニュアル, pp34-35, 診断と治療社, 東京, 2013
 
8) Delellis RA : Surgical pathology of the parathyroid glands. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp605-612, Elsevier, Philadelphia, 2013
 
9) Tominaga Y, Grimelius L, Johansson H, et al : Histological and clinical features of non-familial primary parathyroid hyperplasia. Pathol Res Pract 188 : 115-122, 1992
PubMed
10) Pasieka JL, Parsons LL : A prospective surgical outcome study assessing the impact of parathyroidectomy on symptoms in patients with secondary and tertiary hyperparathyroidism. Surgery 128 : 531-539, 2000
PubMed
11) Silverberg SJ, Bilezikian JP : Primary hyperparathyroidism : pathophysiology, surgical indicasions, and preoperative workup. Surgery of the Thyroid and Parathyroid Glands (Randolf GW, 2nd eds), pp531-538, Elsevier, Philadelphia, 2013
 
P.170 掲載の参考文献
1) Silverberg SJ, et al : Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Maetab 92 : 3803-3808, 2007
 
2) 山本貴之, 冨永芳博 : シナカルセトの適応拡大後の原発性副甲状腺機能亢進症, 副甲状腺癌に対する治療戦略 日内分泌・甲状腺外会誌 31 : 205-209, 2014
 

付章 副甲状腺に関する業績

P.172 掲載の参考文献
1) Takagi H, Tominaga Y, Uchida K, Yamada N, Ishii T, Morimoto T, Yasue M : Preoperative diagnosis of secondary hyperparathyroidism using computed tomography. J Comput Assist Tomogr 6 : 527-528, 1982
PubMed
2) Takagi H, Uchida K, Tominaga Y, Yamada N, Ishii T, Morimoto T, Yasue M : Chronic hypophosphatemia in the renal homograft recipient. Nagoya J Med Sci 44 : 83-87, 1982
PubMed
3) Takagi H, Tominaga Y, Uchida K, Yamada N, Kano T, Kawahara K, Suzuki H : Polymorphism of parathyroid glands in patients with chronic renal failure and secondary hyperparathyroidism. Endocrinol Jpn 30 : 463-468, 1983
PubMed
4) Takagi H, Tominaga Y, Uchida K, Yamada N, Morimoto T, Yasue M : Image diagnosis of parathyroid glands in chronic renal failure. Ann Surg 198 : 74-79, 1983
PubMed
5) Takagi H, Uchida K, Yamada N, Morimoto T, Yasue M, Tominaga Y, Kawai M, Kano T, Kawahara K : Major surgery in patients undergoing hemodialysis. Nagoya J Med Sci 46 : 109-116, 1984
PubMed
6) Takagi H, Tominaga Y, Uchida K, Yamada N, Kawai M, Kano T, Morimoto T : Subtotal versus total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 200 : 18-23, 1984
PubMed
7) Takagi H, Tominaga Y, Uchida K, Yamada N, Kano T, Morimoto T : Comparison of imaging methods for diagnosing enlarged parathyroid glands in chronic renal failure. J Comput Assist Tomogr 9 : 733-737, 1985
PubMed
8) Takagi H, Tominaga Y, Uchida K, Yamada N, Kawai M, Kano T, Funahashi H, Mizuno S : Evaluation of image-diagnosing methods of enlarged parathyroid glands in chronic renal failure. World J Surg 10 : 605-611, 1986
PubMed
9) Takagi H, Tominaga Y, Tanaka Y, Uchida K, Orihara A, Yamada N, Kawai M, Hayashi S, Taira N, Kano T : Total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 208 : 639-644, 1988
PubMed
10) Tominaga Y, Tanaka Y, Uchida K, Kano T, Yamada N, Orihara A, Kawai M, Taira N, Takagi H : Surgical treatment of renal hyperparathyroidism. the result 160 patients. Endocrine Surgery 6 : 59-64, 1989
 
11) Tominaga Y, Grimelius L, Falkmer UG, Johansson H, Falkmer S : DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism. Anal Cell Pathol 3 : 325-333, 1991
PubMed
12) Tominaga Y, Tanaka Y, Sato K, Numano M, Uchida K, Takagi H : Surgical treatment of secondary hyperparathyroidism. J Bone Miner Met 9 : 56-62, 1991
 
13) Tominaga Y, Grimelius L, Johansson H, Rudberg C, Johansson H, Ljunghall S, Bergstrom R, Rastad J, Akerstrom G : Histological and clinical features of non-familial primary parathyroid hyperplasia. Pathol Res Pract 188 : 115-122, 1992
PubMed
14) Tominaga Y, Tanaka Y, Sato K, Numano M, Uchida K, Falkmer U, Grimelius L, Johansson H, Takagi H : Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World J Surg 16 : 595-603, 1992
PubMed
15) Tominaga Y, Uchida K, Sato K, Numano M, Tanaka Y, Takagi H : Parathyroidectomy before and after renal transplantation. Transplant Proc 24 : 1861-1862, 1992
PubMed
16) Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y : Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92 : 1436-1443, 1993
PubMed
17) Tanaka Y, Seo H, Tominaga Y, Funahashi H, Matsui N, Takagi H : Factors related to the recurrent hyperfunction of autografts after total parathyroidectomy in patients with severe secondary hyperparathyroidism. Surg Today 23 : 220-227, 1993
 
18) Tominaga Y, Sato K, Numano M, Tanaka Y, Takagi H : Surgical treatment of renal hyperparathyroidism. Asian J Surg 17 : 121-126, 1994
 
19) Tominaga Y, Numano M, Uchida K, Katayama A, Haba T, Asano H, Sato K, Tanaka Y, Takagi H : Parathyroidectomy for patients with renal hyperparathyroidism refractory to calcitriol pulse therapy. J Bone Miner Met 12 : S99-S104, 1994
 
20) Tominaga Y, Numano M, Uchida K, Sato K, Asano H, Haba T, Katayama A, Yokoyama I, Suzuki K, Tanaka Y, Takagi H : Lung metastasis from parathyroid carcinoma causing recurrent renal hyperparathyroidism in a hemodialysis patient : report of a case. Surg Today 25 : 984-986, 1995
 
21) Tominaga Y, Sato K, Tanaka Y, Numano M, Uchida K, Takagi H : Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 44 : S42-S47, 1995
PubMed
22) Tanaka Y, Funahashi H, Imai T, Tobinaga J, Murase H, Andoh H, Wada M, Matsuyama T, Tominaga Y, Takagi H : Heterotransplantation of human parathyroid glands into nude mice. Endocr J 42 : 9-14, 1995
PubMed
23) Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T, Uchida K, Numano M, Tanaka Y, Takagi H : Clonal analysis of noudular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20 : 744-752, 1996
PubMed
24) Tominaga Y, Sato K, Numano M, Tanaka Y, Uchida K, Asano H, Katayama A, Takagi H : Indication for parathyroidectomy in renal hyperparathyroidism. Acta Chirurgica Austriaca 124 : 10-14, 1996
 
25) Tominaga Y, Tanaka Y, Sato K, Numano M, Uchida K, Asano H, Haba T, Kawai M, Yokoyama I, Takagi H : Supernumerary parathyroid glands in surgery for renal hyperparathyroidism. Acta Chirurgica Austriaca 124 : 16-20, 1996
 
26) Tanaka Y, Tominaga Y, Funahashi H, Sato K, Numano M, Takagi H : Preoperative localization studiese in secondary hyperplasia. Acta Chirurgica Austriaca 142 : 14-16, 1996
 
27) Takagi H, Tominaga Y, Tanaka Y, Sato K, Numano M, Uchida K : Experiences of total para thyroidectomy with forearm autografts for 254 patients with renal hyperparathyroidism. Acta Chirurgica Austriaca 124 : 28-32, 1996
 
28) Tominaga Y, Tanaka Y, Sato K, Numano M, Uchida K, Asano H, Haba T, Falkmer U, Grimelius L, Johansson H, Takagi H : DNA studies in graft-dependent hyperparathyroidism. Acta Chirurgica Austriaca 124 : 65-68, 1996
 
29) Tanaka Y, Funahashi H, Imai T, Wada M, Tominaga Y, Mishra SK, Takagi H : Functional and morphometric study of cryopreserved human parathyroid tissue transplanted into nude mice. World J Surg 20 : 692-699, 1996
PubMed
30) Tanaka Y, Funahashi H, Imai T, Seo H, Tominaga Y, Takagi H : Oxyphil cell function in secondary parathyroid hyperplasia. Nephron 73 : 580-586, 1996
PubMed
31) Uemura O, Goto Y, Iwasa M, Ando T, Sato K, Tominaga Y, Uchida K, Ichiki T, Sugiyama N : Secondary carnitine palmitoyltransferase deficiency in chronic renal failure and secondary hyperparathyroidism. Tohoku J Exp Med 178 : 307-314, 1996
PubMed
32) Tominaga Y, Takagi H : Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens 5 : 336-341, 1996
PubMed
33) Tanaka Y, Funahashi H, Imai T, Tominaga Y, Takagi H : Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism. Semin Surg Oncol 13 : 125-133, 1997
PubMed
34) Uchida K, Tominaga Y, Tanaka Y, Takagi H : Renal transplantation and secondary hyperparathyroidism. Semin Surg Oncol 13 : 97-103, 1997
PubMed
35) Takagi H, Tominaga Y, Tanaka Y, Uchida K : Surgery for renal hyperparathyroidism-experience of 640 cases. Nagoya J Med Sci 60 : 15-22, 1997
PubMed
36) Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H : Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13 : 87-96, 1997
PubMed
37) Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H : Histopathology, pathophysiology and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13 : 78-86, 1997
PubMed
38) Tominaga Y, Johansson H, Johansson H, Takagi H : Secondary hyperparathyroidism : pathophysiology, histopathology, and medical and surgical management. Surg Today 27 : 787-792, 1997
PubMed
39) Tanaka Y, Funahashi H, Imai T, Tominaga Y, Takagi H : Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism. Semin Surg Oncol 13 : 125-133, 1997
PubMed
40) Sato K, Tominaga Y, Ichikawa F, Uchida K, Tsuchiya T, Kubodera N, Takagi H : Suppression of parathyroid hormone secretion by 22-oxa-calcitriol in human parathyroid hyperplasia due to uremia in vitro. Nephrology 4 : 177-182, 1998
 
41) Numano M, Tominaga Y, Uchida K, Orihara A, Tanaka Y, Takagi H : Surgical significance of supernumerary parathyroid glands in renal hyperarathyroidism. World J Surg 22 : 1098-1103, 1998
 
42) Tominaga Y, Uchida K, Haba T, Katayama A, Yamada K, Sato T, Hibi Y, Tsuzuki T, Tanaka Y, Takagi H : Thyroid lesions in patients with renal hyperparathyroidism. Thyroidol Clin Exp 10 : 275-277, 1998
 
43) Funahashi H, Tanaka Y, Imai T, Wada M, Tsukamura K, Hayakawa Y, Matsuura N, Kikumori T, Oiwa M, Tominaga Y, Takagi H : Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia. J Endocrinol Invest 21 : 43-47, 1998
PubMed
44) Tanaka Y, Imai T, Matuura N, Oiwa M, Kikumori T, Mase T, Shibata A, Hayashi H, Hayakawa Y, Wada M, Tominaga Y, Funahashi H : Normal parathyroid autotransplantation in operations for differentiated thyroid cancer : an experimental transplant study on nude mice. Thyroidl Clin Exp 10 : 271-273, 1998
 
45) Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, Yamada K, Numano M, Tanaka Y, Takagi H : Expression of PRAD1-cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 55 : 1375-1383, 1999
PubMed
46) Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kurokawa K : Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patients-the Japanese strategy. Nephrol Dial Transplant 14 : 2574-2577, 1999
 
47) Tominaga Y : Surgical management of secondary hyperparathyroidism in uremia. Am J Med Sci 317 : 390-397, 1999
PubMed
48) Tominaga Y : Mechanism of parathyroid tumourigenesis in uraemia. Nephrol Dial Transplant 14 (Suppl) : 63-65, 1999
 
49) Hayakawa Y, Tanaka Y, Funahashi H, Imai T, Matsuura N, Oiwa M, Kikumori T, Mase T, Tominaga Y, Nakao A : Hyperphosphatemia accelerates parathyroid cell proliferation and parathyroid hormone secretion in severe secondary parathyroid hyperplasia. Endocr J 46 : 681-686, 1999
PubMed
50) Fukagawa M, Tominaga Y, Kitaoka M, Kakuta T, Kurokawa K : Medical and surgical aspects of parathyroidectomy. Kidney Int Suppl 73 : S65-S69, 1999
PubMed
51) Tominaga Y : Management of renal hyperparathyroidism. Biomed Pharmacother 54 (Suppl 1) : 25-31, 2000
 
52) Tanaka Y, Naruse T, Funahashi H, Imai T, Suzumura K, Mase T, Tominaga Y : Bone metabolic analysis in patients with primary hyperparathyroidism. Biomed Pharmacother 54 (Suppl 1) : 97-99, 2000
 
53) Hibi Y, Tominaga Y, Uchida K, Takagi H, Imai H, Funahashi H, Nakao A : Preoperative imaging diagnosis for persistent renal hyperparathyroidism. Asian J Surg 24 : 153-159, 2001
 
54) Yajima A, Tanaka K, Tominaga Y, Ogawa Y, Tanizawa T, Inou T, Otsubo O, Otsubo K : Early changes of bone histology and circulating markers of bone turnover after parathyroidectomy in hemodialysis patients with severe hyperparathyroidism. Clin Nephrol 56 : 27-34, 2001
PubMed
55) Sato T, Tominaga Y, Iwasaki Y, Kazama JJ, Shigematsu T, Inagaki H, Watanabe I, Katayama A, Haba T, Uchida K, Fukagawa M : Osteoprotegerin levels before and after renal transplanta tion. Am J Kidney Dis 38 (Suppl 1) : S175-S177, 2001
 
56) Tominaga Y, Uchida K, Haba T, Katayama A, Sato T, Hibi Y, Numano M, Tanaka Y, Inagaki H, Watanabe I, Hachisuka T, Takagi H : More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 38 (Suppl 1) : S168-S171, 2001
 
57) Tominaga Y : Uremic calciphylaxis syndrome : calcified uremic artheriolopathy. Internal Med 40 : 1174-1175, 2001
 
58) Fukagawa M, Kitaoka M, Tominaga Y, Kurokawa K : Imaging and intervention of parathyroid hyperplasia. The Spectrum of Renal Osteodystrophy, pp421-438, Oxford Medical Publications, 2001
 
59) Hibi Y, Tominaga Y, Sato T, Katayama A, Haba T, Uchida K, Ichimori T, Numano M, Tanaka Y, Takagi H, Imai T, Funahashi H, Nakao A : Reoperatin for renal hyperparathyroidism. World J Surg 26 : 1301-1307, 2002
 
60) Hibi Y, Tominaga Y, Uchida K, Takagi H, Imai T, Funahashi H, Nakao A : Cases with fewer than four parathyroid glands in patients with renal hyperparathyroidism at initial parathyroidectomy. World J Surg 26 : 314-317, 2002
PubMed
61) Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kakuta T, Onoda N, Koiwa F, Yumita S, Kurokawa K；for the Japanese Society for Parathyroid Intervention : Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant 18 (Suppl 3) : iii31-iii33, 2003
 
62) Tominaga Y, Katayama A, Sato T, Matsuoka S, Goto N, Haba T, Hibi Y, Numano M, Ichimori T, Uchida K : Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant 18 (Suppl 3) : iii65-iii70, 2003
 
63) Sato T, Inagaki A, Uchida K, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Tominaga Y, Okajima Y, Ohta K, Suga H, Taguchi S, Kakiya S, Itatsu T, Kobayashi T, Nakao A : Diabetes mellitus after transplant : relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 76 : 1320-1326, 2003
PubMed
64) Yajima A, Ogawa Y, Takahashi HE, Tominaga Y, Inou T, Otsubo O : Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kideney Dis 42 : 729-738, 2003
 
65) Miyazaki S, Igarashi M, Nagata A, Tominaga Y, Onodera K, Komoda T : Development of immunoassays for type-5 tartrate-resistant asid phosphatase in human serum. Clin Chim Acta 329 : 109-115, 2003
 
66) Tanaka M, Tominaga Y, Sawatari E, Itoh K, Matsushita K, Matsushita K, Matsuoka S, Ueki T, Goto N, Sato T, Katayama A, Haba T, Uchida K : Infarction of mediastinal parathyroid gland causing spontaneous remission of secondary hyperparathyroidisim. Am J Kideney Dis 44 : 762-767, 2004
 
67) Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M : Total parathyroidectomy reduces elevated circulating fibroblasat growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44 : 481-487, 2004
PubMed
68) Tominaga Y, Matsuoka S, Sato T : Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease. Ther Apher Dial 9 : 44-47, 2005
PubMed
69) Matsuoka S, Tominaga Y, Uno N, Goto N, Sato T, Katayama A, Haba T, Uchida K, Kobayashi K, Nakao A : Calciphylaxis : a rare complication of patients who required parathyroidectomy for advanced renal hyperparathyroidism. World J Surg 29 : 632-635, 2005
PubMed
70) Goto N, Tominaga Y, Matsuoka S, Sato T, Katayama A, Haba T, Uchida K : Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients；special focus on dilated cardiomyopathy. Clin Exp Nephrol 9 : 138-141, 2005
PubMed
71) Tanaka M, Ito K, Matsushita K, Matsushita K, Tominaga Y, Matsuoka S, Ueki T, Goto N, Sato T, Katayama A, Haba T, Uchida K : Usefulness of power Doppler ultrasonography for the diagnosis of autoinfarction of parathyroid gland in secondary hyperparathyroidism. Clin Calcium 15 (Suppl 1) : 46-50, 2005
 
72) Tahara H, Yumita S, Ishida M, Tsuruta Y, Cunningham J, Fukagawa M, Tominaga Y, Tokumoto M, Onoda N : Present status and problems in vitamin D and sevelamer therapy (discussion). Clin Calcium 15 (Suppl 1) : 225-228, 2005
 
73) Hibi Y, Kambe F, Tominaga Y, Mizuno Y, Kobayashi H, Iwase K, Imai T, Seo H : Up-regulation of the gene encoding protein kinase A type I α regulatory subunit in nodular hyperplasia of parathyroid glands in patients with chronic renal failure. J Clin Endocrinol Metab 91 : 563-568, 2006
 
74) Tominaga Y, Inaguma D, Matsuoka S, Tahara H, Kukita K, Kurihara S, Onoda N, Tsuruta Y, Tsutsui S, Ohta K, Kuwahara M, Tanaka M, Nishizawa Y (PTG study group) : Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 10 : 198-204, 2006
 
75) Tanaka M, Tominaga Y, Itoh K, Matsushita K, Matsushita K, Matsuoka S, Ueki T, Goto N, Sato T, Katayama A, Haba T, Uchida K : Autoinfarction of the parathyroid gland diagnosed by power Doppler ultrasonography in a patients with secondary hyperparathyroidism. Nephrol Dial Transplant 21 : 1092-1095, 2006
 
76) Dusso AS, Sato T, Arcidiacono MV, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, Tominaga Y, Slatopolsky E : Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl 102) : S8-S11, 2006
PubMed
77) Tominaga Y : Surgical treatment of secondary hyperparathyroidism due to chronic kidney disease. Ups J Med Sci 111 : 277-292, 2006
PubMed
78) Matsuoka S, Tominaga Y, Uno N, Goto N, Sato T, Katayama A, Uchida K, Nakao A : Surgical significance of undescended parathyroid gland in renal hyperparathyroidism. Surgery 139 : 815-820, 2006
PubMed
79) Matsuoka S, Tominaga Y, Sato T, Uno N, Goto N, Katayama A, Uchida K, Tsuzuki T : Recur rent renal hyperparathyroidism caused by parathyromatosis. World J Surg 31 : 299-305, 2007
 
80) Matsuoka S, Tominaga Y, Sato T, Uno N, Goto N, Katayama A, Uchida K, Takami H : QuiCk-intraOperative Bio-intact PTH assay at parathyroidectomy for secondary hyperparathyroidism. World J Surg 31 : 824-831, 2007
PubMed
81) Yajima A, Inaba M, Tominaga Y, Ito A : Miniimodeling reduces the rate of cortical bone loss in patients with secondary hyperparathyroidism. Am J Kidney Dis 49 : 440-451, 2007
PubMed
82) Tominaga Y, Matsuoka S, Sato T, Uno N, Goto N, Katayama A, Haba T, Uchida K (Yagoto PTx Forum) : Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy. Ther Apher Dial 11 : 266-273, 2007
 
83) Yajima A, Inaba M, Ogawa Y, Tominaga Y, Tanizawa T, Inou T, Otsubo O : Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol Dial Transplant 22 : 1645-1657, 2007
PubMed
84) Dusso AS, Arcidiacono MV, Sato T, Alvarez-Hemandez D, Yang J, Gonzalez-Suarez I, Tominaga Y, Slatopolsky E : Molecular basis of parathyroid hyperplasia. J Ren Nutr 17 : 45-47, 2007
 
85) Yamashiro N, Tominaga Y, Matsuoka S, Uno N, Goto N, Sato T, Katayama A, Hashiba M, Tsuzuki T, Uchida K : A supernumerary parathyroid gland located in an unusual site, parapharyngeal space, in a patient with persistent renal hyperparathyroidism. Nephrol Dial Transplant 23 : 419-420, 2008
 
86) Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Tokumoto M, Gonzalez-Suarez I, Lu Y, Tominaga Y, Cannata-Andia J, Slatopolsky E, Dusso AS : EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 19 : 310-320, 2008
 
87) Eriguchi R, Umakoshi J, Tominaga Y, Sato Y : Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl. Nephrol Dial Transplant Plus 1 : 218-220, 2008
 
88) Tominaga Y, Tsuzuki T, Matsuoka S, Uno N, Sato T, Shimabukuro S, Goto N, Nagasaka T, Uchida K : Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg 32 : 815-821, 2008
PubMed
89) Tominaga Y : Current status of parathyroidectomy for secondary hyperparathyroidism in Japan. Nephrol Dial Transplant Plus (Suppl 3) : iii35-iii38, 2008
 
90) Komaba H, Takeda Y, Shin J, Tanaka R, Kakuta T, Tominaga Y, Fukagawa M : Reversed whole PTH-intact PTH ratio as an indicator of marked parathyroid enlargement : five case studies and a literature review. Neprol Dial Transplant Plus 1 (Suppl 3) : iii54-iii58, 2008
 
91) Onoda N, Fukagawa M, Tominaga Y, Kitaoka M, Akizawa T, Koiwa F, Kakuta T, Kurokawa K；for the Japanese Society for Parathyroid Intervention : New clinical guideline for selective direct injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant Plus (Suppl 3) : iii26-iii28, 2008
 
92) Kakuta T, Fukagawa M, Kitaoka M, Koiwa F, Onoda N, Tominaga Y, Akizawa T, Kurokawa K, for the Japanese Society for Parathyroid Intervention : Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan : 2004 survey by the Japanese Society for parathyroid intervention. Nephrol Dial Transplant Plus (Suppl 3) : iii21-iii25, 2008
 
93) Tominaga Y, Matsuoka S, Uno N, Sato T : Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 12 (Suppl 1) : S21-S26, 2008
 
94) Matsuoka S, Tominaga Y, Sato T, Uno N, Hiramitsu T, Goto N, Nagasaka T, Uchida K : Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism. Ther Apher Dial 12 : 391-395, 2008
 
95) Uno N, Tominaga Y, Matsuoka S, Tsuzuki T, Shimabukuro S, Sato T, Goto N, Nagasaka T, Katayama A, Uchida K : Incidence of parathyroid glands located in thymus in patients with renal hyperparathyroidism. World J Surg 32 : 2516-2519, 2008
PubMed
96) Yajima A, Inaba M, Tominaga Y, Ito A : Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 74 : 775-781, 2008
PubMed
97) Sato K, Tominaga Y, Ichikawa F, Uchida K, Takezawa J, Tsuchiya T, Kubodera N, Takagi H : In vitro suppression of parathyroid hormone secretion by 22-oxa-calcitriol in human parathyroid hyperplasia due to uraermia. Nephrology 4 : 177-182, 2008
 
98) Nakai S, Akiba T, Kazama J, Yokoyama Y, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y : Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in japan. Ther Apher Dial 12 : 49-54, 2008
 
99) Nanasato M, Goto N, Isobe S, Unno K, Hirayama H, Sato T, Matsuoka S, Nagasaka T, Tominaga Y, Uchida K, Murohara T : Restored cardiac conditions and left ventricular function after parathyroidectomy in a hemodialysis patient-parathyroidectomy improves cardiac fatty acid metabolism assesed by 123I-BMIPP-. Circ J 73 : 1956-1960, 2009
 
100) Sato T, Fukagawa M, Uchida K, Katayama A, Nagasaka T, Matsuoka S, Goto N, Tominaga Y, Kobayashi T, Nakao A : 1,25-dihydroxyvitamin D synthesis after renal transplantation : the role of fibroblast growth factor 23 and cyclosporine. Clin Transplant 23 : 368-374, 2009
PubMed
101) Tominaga Y, Matsuoka S, Uno N, Tsuzuki T, Hiramitsu T, Goto N, Nagasaka T, Watarai Y, Uchida K : Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis. World J Surg 33 : 2335-2342, 2009
 
102) Tominaga Y, Matsuoka S, Uno N : Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients. World J Surg 34 : 1312-1317, 2010
PubMed
103) Tominaga Y : Cinacalcet HCL treatment in patients with chronic kidney disease stage 3-4. Clin Med Ther 1 : 1465-1466, 2009
 
104) Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M : Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 : 232-238, 2010
PubMed
105) Tominaga Y : Surgical and medical management of tertiary hyperparathyroidism. World J Endocr Surg 2 : 105-109, 2010
 
106) Yajima A, Inaba M, Tominaga Y, Nishizawa Y, Ikeda K, Ito A : Increased osteocyte death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism. J Bone Miner Res 25 : 2374-2381, 2010
PubMed
107) Sato T, Kikkawa Y, Hiramitsu T, Yamamoto T, Goto N, Matsuoka S, Nagasaka T, Watarai Y, Uchida K, Tominaga Y : Role of multifunctional cell cycle modulators in advanced secondary hyperparathyroidism. Ther Apher Dial 15 : 26-32, 2011
PubMed
108) Okada M, Tominaga Y, Izumi K, Nobata H, Yamamoto T, Hiramitsu T, Tsujita M, Goto N, Nanmoku K, Watarai T, Uchida K : Tertiary hyperparathyroidism resistant to cinacalcet treatment. Ther Apher Dial 15 : 33-37, 2011
PubMed
109) Tanaka M, Tokunaga K, Maruyama T, Otagiri M, Tominaga Y, Itoh K, Matsushita K, Komaba H, Fukagawa M : Parathyroidectomy markedly reduces oxidative stress in a patient with primary hyperparathyroidism. Ther Apher Dial 15 (Suppl 1) : 38-41, 2011
 
110) Hashimoto K, Morimoto A, Kato M, Tominaga Y, Maeda N, Tsuzuki T, Yokoi T, Nagasaka T : Immunocytochemical analysis for differential diagnosis of thyroid lesions using liquid-based cytology. Nagoya J Med Sci 73 : 15-24, 2011
PubMed
111) Taniguchi M, Tanaka M, Hamano T, Nakanishi S, Fujii H, Kato H, Koiwa F, Ando R, Kimata N, Akiba T, Kono T, Yokoyama K, Shigemathu T, Kakuta T, Kazama JJ, Tominaga Y, Fukagawa M : Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 15 : 42-49, 2011
 
112) Yajima A, Tominaga Y, Satoh S, Otsubo S, Inaba M, Nitta K, Ito A : Morphological analysis of bone dynamics and metabolic bone disease. A case report of recurrent renal hyperparathyroidism. Clin Calcium 21 : 603-608, 2011
PubMed
113) Tominaga Y : Surgical management of secondary and tertiary hyperparathyroidism. Gregory W Randolph, Surgery of the Thyroid and Parathyroid Glands, Second Edition, Elsevier, 639-647, 2012
 
114) Yamamoto T, Tominaga Y, Tsuzuki T, Hiramitsu T, Nanmoku K : Metastatic prostate carcinoma detected at lymph node dissection for thyroid papillary carcinoma : report of a case. Int Canc Conf J 1 : 24-26, 2012
 
115) Yajima A, Inaba M, Tominaga Y, Tanaka M, Otsubo S, Nitta K, Ito A, Satoh S : Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease. Ther Apher Dial 17 (Suppl 1) : 41-48, 2013
 
116) Nobata H, Tominaga Y, Imai H, Uchida K : Hypocalcemia immediately after renal transplantation. Clin Transplant 27 : E644-648, 2013
PubMed
117) Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M : Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 19 : 225-234, 2015
 
118) Tsujita M, Inaguma D, Goto N, Yamamoto T, Hiramitsu T, Katayama A, Takeda A, Kobayashi T, Morozumi K, Uchida K, Narumi S, Watarai Y, Tominaga Y : Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients. Clin Exp Nephrol 19 : 319-324, 2015
 
119) Hiramitsu T, Tominaga Y, Okada M, Yamamoto T, Kobayashi T : A retrospective study of the impact of intraoperative intact parathyroid hormone monitoring during total parathyroidectomy for secondary hyperparathyroidism : STARD Study. Medicine 94 : e1213, 2015
PubMed
120) Ito K, Goto N, Futamura K, Okada M, Yamamoto T, Tsujita M, Hiramitsu T, Narumi S, Tominaga Y, Watarai Y : Death and kidney allograft dysfunction after bacteremia. Clin Exp Nephrol 20 : 309-315, 2016
PubMed
121) Tominaga Y, Kakuta T, Yasunaga C, Nakamura M, Kadokura Y, Tahara H : Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the Parathyroid Surgeons' Society of Japan. Ther Apher Dial 20 : 6-11, 2016
PubMed
122) Yamamoto T, Tominaga Y, Okada M, Hiramitsu T, Tsujita M, Goto N, Narumi S, Watarai Y : Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg 40 : 600-606, 2016
PubMed
P.182 掲載の参考文献
1) 高木弘, 冨永芳博, 打田和治, 山田宣夫, 石井高博, 森本剛史, 安江満悟, 加納忠行, 渡辺有三 : 腎性上皮小体機能亢進症の診断と治療. 腎と透析 11 : 295-302, 1981
 
2) 高木弘, 安江満悟, 森本剛史, 石井高博, 打田和治, 山田宣夫, 冨永芳博, 浅井一, 両角国男, 山崎親雄, 増子和郎, 川原弘久, 成田真康 : 腎性副甲状腺機能亢進症に対する外科的治療. 日外会誌 81 : 791-801, 1981
 
3) 高木弘, 森本剛史, 安江満悟, 冨永芳博, 打田和治, 山田宣夫, 石井高博, 吉田篤博, 加納忠行, 川原勝彦 : 腎性骨異栄養症に対する上皮小体摘出術とその適応. 日本医事新報 3022 : 25-29, 1982
 
4) 高木弘, 森本剛史, 赤座達也, 安江満悟, 打田和治, 山田宣夫, 石井高博, 冨永芳博, 吉田篤博, 加村ひろみ, 小原節子 : 移植腎機能の特性. 移植 17 : 25-30, 1982
 
5) 高木弘, 打田和治, 冨永芳博, 山田宣夫, 石井高博, 河合真千夫, 森本剛史, 安江満悟, 加納忠行, 川原勝彦 : 腎移植患者と骨カルシウム. 腎と透析 13 : 81-87, 1982
 
6) 冨永芳博, 高木弘, 打田和治, 山田宣夫, 河合真千夫, 鈴木春見, 森本剛史, 安江満悟, 吉田篤博, 後藤 泉, 加納忠行, 川原勝彦, 石井高博, 両角國男 : 腎性上皮小体機能亢進症に対する上皮小体全摘出術と自家移植術. 透析会誌 16 : 149-155, 1983
 
7) 高木弘, 冨永芳博, 石井高博, 打田和治, 山田宣夫, 森本剛史, 安江満悟, 加納忠行, 川原勝彦 : 腎性骨異栄養症における上皮小体画像診断の意義について. 日外会誌 83 : 352-356, 1983
 
8) 高木弘, 冨永芳博 : 続発性上皮小体機能亢進症. 内分泌外科 1 : 189-197, 1984
 
9) 冨永芳博, 打田和治, 山田宣夫, 河合真千夫, 加納忠行, 川原勝彦, 高木弘, 森本剛史, 安江満悟 : 腎性上皮小体機能亢進症の診断と外科的治療. 泌尿紀要 30 : 989-992, 1984
 
10) 冨永芳博, 高木弘, 鈴木春見, 近藤達平 : 腎性上皮小体機能亢進症の病理組織学的特性と臨床像. 日外会誌 86 : 630-639, 1985
 
11) 高木弘, 冨永芳博 : 腎性上皮小体機能亢進症-外科治療. 腎と骨代謝 19 : 1185-1187, 1985
 
12) 高木弘, 打田和治, 冨永芳博, 山田宣夫, 加納忠行, 河合真千夫, 森本剛史 : 腎性上皮小体機能亢進症の治療. 臨牀透析 1 : 1721-1730, 1985
 
13) 高木弘, 冨永芳博, 打田和治, 山田宣夫, 加納忠行, 折原明, 仲西直治, 河合真千夫 : 上皮小体機能亢進症. 腎と透析 21 : 23-28, 1986
 
14) 冨永芳博, 高木弘, 打田和治, 山田宣夫, 加納忠行, 河合真千夫 : 二次性上皮小体機能亢進症の外科治療に関する問題点とその対策. 透析会誌 19 : 437-445, 1986
 
15) 冨永芳博, 高木弘 : 腎性上皮小体機能亢進症における上皮小体摘出術の適応. 臨牀透析 2 : 1088-1089, 1986
 
16) 冨永芳博, 打田和治, 山田宣夫, 河合真千夫, 仲西直治, 加納忠行, 高木弘 : 上皮体の画像診断. 画像情報 18 : 618-620, 1986
 
17) 冨永芳博 : 腎性上皮小体機能亢進症をめぐって. 内分泌外科 3 : 52-69, 1986
 
18) 冨永芳博, 打田和治, 高木弘 : 移植後合併症 (1) 骨合併症 (二次性上皮小体機能亢進症). 臨牀透析 3 : 1935-1942, 1987
 
19) 冨永芳博, 高木弘 : 続発性上皮小体機能亢進症. ホルモンと臨床 35 : 979-985, 1987
 
20) 冨永芳博, 田中勇治, 高木弘 : 続発性上皮小体機能亢進症. 外科治療 29 : 178-186, 1987
 
21) 冨永芳博, 打田和治, 山田宣夫, 折原明, 河合真千夫, 田中勇治, 森本剛史, 加納忠行, 佐竹満, 平昇, 加藤裕, 幅俊人, 浅野浩史, 林衆治, 高木弘 : 腎移植後のホルモン調節-上皮小体機能. 臨牀透析 3 : 527-534, 1987
 
22) 田中勇治, 冨永芳博, 打田和治, 山田宣夫, 折原明, 幅俊人, 平昇, 加藤裕, 河合真千夫, 林衆治, 蜂須賀丈博, 加納忠行, 高木弘 : 二次性上皮小体機能亢進症に対する上皮小体摘出術後の管理. 腎と骨代謝 1 : 287-294, 1988
 
23) 冨永芳博, 田中勇治, 打田和治, 山田宣夫, 加納忠行, 折原明, 河合真千夫, 幅俊人, 浅野浩史, 加藤裕, 林衆治, 高木弘 : 腎性上皮小体機能亢進症の再発例の検討. 腎と骨代謝 1 : 369-380, 1988
 
24) 高木弘, 冨永芳博, 田中勇治 : 上皮小体. 外科 50 : 1117-1124, 1988
 
25) 高木弘, 冨永芳博, 田中勇治, 打田和治 : 上皮小体の機構および機能異常-続発性上皮小体機能亢進症. 新外科学大系第15巻, pp367-408, 中山書店, 1989
 
26) 田中勇治, 冨永芳博, 佐藤圭介, 高木弘 : tertiary hyperparathyroidism. THE BONE 3 : 71-82, 1989
 
27) 冨永芳博, 田中勇治, 打田和治, 加納忠行, 山田宣夫, 河合真千夫, 高木弘 : 腎性上皮小体機能亢進症における過剰・異所性上皮小体に対する術前画像診断. 日外会誌 90 : 1057-1064, 1989
 
28) 冨永芳博, 田中勇治, 打田和治, 加納忠行, 山田宣夫, 河合真千夫, 高木弘 : 腎性上皮小体機能亢進症の部位診断としての画像診断の意義. 腎と骨代謝 2 : 315-323, 1989
 
29) 冨永芳博, 田中勇治, 河合真千夫, 打田和治, 山田宣夫, 森はつみ, 後 峰代, 安田直津子, 伊藤はつ子, 高木弘 : 甲状腺, 上皮小体. 臨牀透析 5 : 1183-1204, 1989
 
30) 冨永芳博 : 続発性上皮小体機能亢進症, 術後再発と再手術. 内分泌外科 6 : 131-165, 1989
 
31) 冨永芳博, 高木弘 : 上皮小体の外科. 外科治療 62 : 165-173, 1990
 
32) 冨永芳博, 田中勇治, 打田和治, 加納忠行, 山田宣夫, 折原明, 河合真千夫, 平昇, 加藤裕, 幅俊人, 林衆治, 高木弘 : 腎性上皮小体機能亢進症手術後の移植上皮小体機能について. 腎と骨代謝 3 : 327-336, 1990
 
33) 冨永芳博, 高木弘 : 二次性 (腎性) 上皮小体機能亢進症-外科から. 臨床外科 45 : 1567-1571, 1990
 
34) 冨永芳博, 高木弘 : 腎性上皮小体機能亢進症-外科治療. 腎と透析29 (増) 腎・尿路疾患診療指針' 90 : 437-439, 1990
 
35) 田中勇治, 冨永芳博, 林衆治, 佐藤圭介, 打田和治 : 腎性上皮小体機能亢進症に対する上皮小体全摘出後前腕筋肉内自家移植術後の上皮小体ホルモンの変化. 日本外科学会雑誌 92 : 57-63, 1991
 
36) 冨永芳博, 佐藤圭介, 沼野正浩, 打田和治, 田中勇治, 高木弘 : 上皮小体摘出術-外科側からの評価と最近の適応. 腎と骨代謝 4 : 333-339, 1991
 
37) 佐藤圭介, 冨永芳博, 沼野正治, 浅野浩史, 小林孝彰, 児島泰樹, 打田和治, 河合真千夫, 田中勇治, 幅俊人, 高木弘 : 異所性石灰化からみた腎性上皮小体機能亢進症と手術適応. 腎と骨代謝 4 : 405-411, 1991
 
38) 冨永芳博, 河合真千夫, 高木弘 : 腎性上皮小体機能亢進症の手術. 内分泌外科標準手術アトラス, pp143-152, インターメルク, 1992
 
39) 冨永芳博, 高木弘 : 続発性上皮小体機能亢進症の病態と治療. THE BONE 6 : 93-101, 1992
 
40) 高木弘, 冨永芳博 (共著) : 腎性上皮小体機能亢進症の外科, 医歯薬出版, 1993
 
41) 冨永芳博, 高木弘 : 腎移植で透析患者の骨病変は改善できるか. 透析フロンティア 3 : 14-17, 1993
 
42) 冨永芳博 : 腎性上皮小体機能亢進症における上皮小体摘出術の適応. 臨牀透析 9 : 961-963, 1993
 
43) 冨永芳博 : スウェーデンにおける原発性上皮小体機能亢進症. ホルモンと臨床 41 : 41-46, 1993
 
44) 冨永芳博 : 腎性上皮小体機能亢進症に対する手術適応. 医学のあゆみ 167 : 36-40, 1993
Medical*Online
45) 冨永芳博 : 二次性副甲状腺機能亢進症に関する研究. 平成4年度厚生科学研究腎不全医療研究事業研究報告書, pp110-113, 1993
 
46) 両角國男, 打田和治, 冨永芳博, 横山逸男, 高木弘 : 再透析症例はどのように管理すべきか (3) 内科医の立場から. 臨牀透析 9 : 83-88, 1993
 
47) 水本大城, 湯沢由紀夫, 渡辺有三, 青井直樹, 冨永芳博 : 慢性腎不全に合併した原発性上皮小体機能亢進症2例の診断と治療. 腎と骨代謝 6 : 497-501, 1993
 
48) 田中勇治, 舟橋啓臣, 今井常夫, 冨永芳博, 高木弘 : 画像診断. 内分泌外科 11 : 17-22, 1994
 
49) 冨永芳博 : 二次性副甲状腺機能亢進症に関する研究. 平成5年度厚生科学研究腎不全医療研究事業研究報告書, 71-73, 1994
 
50) 冨永芳博 : 上皮小体摘出術後の骨の変化. CLINCAL CALCIUM 4 : 54-56, 1994
 
51) 冨永芳博, 沼野正浩, 佐藤圭介, 田中勇治, 高木弘 : 上皮小体摘出術 (PTx). 臨牀透析 10 (増) : 687-698, 1994
 
52) 冨永芳博, 打田和治, 高木弘 : 腎性骨症 外科的治療. 越川昭三 (編) : 透析療法における合併症, pp379-384, 医療ジャーナル社, 1994
 
53) 冨永芳博 : パルス療法の問題点-外科から. 腎と骨代謝 8 : 199-206, 1995
 
54) 冨永芳博 : 腎性上皮小体機能亢進症に対する上皮小体摘出術. 第17回名古屋腎カンファレンス講演集, pp27-36, 1995
 
55) 冨永芳博 : 上皮小体 (副甲状腺) の手術療法について. 全腎協 149 : 22, 1995
 
56) 冨永芳博, 高木弘 : 二次性上皮小体機能亢進症に対する上皮小体摘出術の適応と予後. 阿岸鉄三 (編) : 血液浄化におけるコントラヴァシー (異論・争論), pp183-189, 金原出版, 1995
 
57) 冨永芳博, 高木弘 : 腎性骨異栄養症に対する外科手術. medicina 32 : 2076-2077, 1995
 
58) 冨永芳博, 打田和治, 高木弘 : 腎移植後の再透析例の骨変化について-成人例. 腎と骨代謝 8 : 383-388, 1995
 
59) 冨永芳博 : 副甲状腺摘除術の適応基準. 第38回日本腎臓学会学術総会記念 : 腎臓病学の診断アプローチ, p170, 1995
 
60) 田中勇治, 舟橋啓臣, 今井常夫, 高木弘, 冨永芳博 : 上皮小体の手術. 外科治療 72 : 624-627, 1995
 
61) 高見博, 三村孝, 小原孝男, 中澤英樹, 小林信や, 舟橋啓臣, 冨永芳博 : 原発性上皮小体機能亢進症における尿中I型コラーゲン架橋N-ペプチド (NTx) 測定の臨床的意義. ホルモンと臨床 44 : 321-326, 1995
 
62) 田中勇治, 舟橋啓臣, 今井常夫, 冨永芳博, 高木弘 : 上皮小体機能亢進症手術. 臨床外科 50 : 22-28, 1995
 
63) 田中勇治, 舟橋啓臣, 今井常夫, 冨永芳博, 高木弘 : 上皮小体腫瘍. 外科治療 75 : 177-182, 1996
Medical*Online
64) 冨永芳博, 打田和治, 幅俊人, 高木弘 : 長期透析患者における腎移植-第40回日本透析医学会ワークショップより-. 透析会誌 29 : 351-358, 1996
 
65) 冨永芳博 : 副甲状腺細胞の増殖調節と腫瘍化機構. 腎と骨代謝 9 : 299-306, 1996
 
66) 冨永芳博 : 上皮小体過形成の原因. CLINCAL CALCIUM 6 : 50-52, 1996
 
67) 冨永芳博 : 二次性上皮小体 (副甲状腺) 機能亢進症. 日本医師会雑誌 115 : 1868, 1996
 
68) 冨永芳博, 打田和治, 高木弘 : 腎性上皮小体機能亢進症の外科的治療. 腎と透析 40 別冊腎不全外科' 96 : 92-96, 1996
 
69) 冨永芳博 : 魅惑な, 小さな臓器-上皮小体. 臨牀透析 12 : 1241-1242, 1996
 
70) 冨永芳博, 田中勇治, 高木弘 : 慢性透析患者の副甲状腺機能低下症 (6) PTx後の副甲状腺機能. 臨牀透析 13 : 107-113, 1997
 
71) 冨永芳博, 長坂隆治, 田中勇治, 高木弘 : 副甲状腺の画像診断. 臨牀透析 13 : 39-45, 1997
 
72) 冨永芳博 : invited commentary. 内分泌外科 14 : 56, 1997
 
73) 冨永芳博 : 透析こぼれ話. 透析ケア 3 : 108-109, 1997
 
74) 冨永芳博, 田中勇治, 高木弘 : 病理組織と病態生理. 内分泌外科 14 : 87-95, 1997
 
75) 冨永芳博 : 原発性上皮小体機能亢進症. 日本臨牀別冊腎臓症候群 : 175-177, 1997
 
76) 冨永芳博, 打田和治, 高木弘 : 治療 (4) 腎移植の効果. 臨牀透析 13 : 1269-1274, 1997
 
77) 田中勇治, 冨永芳博, 舟橋啓臣, 今井常夫, 高木弘 : 再発, 持続性上皮小体機能亢進症による再手術. 内分泌外科 14 : 109-112, 1997
 
78) 渡辺有三, 冨永芳博 : 腎性骨異栄養症 移植期腎不全. 黒川清 (監修) : 腎と骨代謝ハンドブック, pp210-220, 日本メディカルセンター, 1997
 
79) 冨永芳博 : 二次性上皮小体機能亢進症の分子生物学. 医学のあゆみ 183 : 338-343, 1997
Medical*Online
80) 冨永芳博 : 二次性上皮小体機能亢進症の上皮小体組織像と臨床像. CLINCAL CALCIUM 8 : 620-623, 1998
 
81) 冨永芳博, 打田和治 : アミロイドーシス. 泌尿器外科 11 : 1137-1140, 1998
Medical*Online
82) 冨永芳博, 打田和治, 高木弘 : 腎性骨異栄養症と二次性上皮小体機能亢進症. 腎と透析 45 : 502-505, 1998
 
83) 冨永芳博, 打田和治, 高木弘 : 上皮小体機能と腎性骨症. 高橋公太 (編) : 腎移植後のフォローアップ, pp299-308, 日本医学館, 1998
 
84) 幅俊人, 打田和治, 冨永芳博 : 消化器症状. 高橋公太 (編) : 腎移植後のフォローアップ, pp208-214, 日本医学館, 1998
 
85) 一森敏弘, 冨永芳博, 日比八束, 山田和弘, 片山昭男, 幅俊人, 打田和治, 吉田篤博, 高木弘 : 硬化性被嚢性腹膜炎に対して外科的治療が有効であった1例. 腎と透析 44 別冊腎不全外科' 98 : 50-52, 1998
 
86) 一森敏弘, 冨永芳博, 日比八束, 山田和弘, 片山昭男, 幅俊人, 打田和治, 高木弘 : 上皮小体全摘出後前腕筋肉内自家移植術の移植腺再発診断におけるmagnetic resonance (MR) の有用性. 腎と透析 44 別冊腎不全外科' 98 : 65-66, 1998
 
87) 冨永芳博 : 慢性腎不全患者の無形成骨 質疑応答. 日本医事新報 3905 : 103-105, 1999
 
88) 冨永芳博 : 副甲状腺過形成の分子生物学. 黒川清 (監修) : 透析骨病変, pp53-65, 日本メディカルセンター, 1999
 
89) 冨永芳博 : 副甲状腺摘出術と術後管理. 黒川清 (監修) : 透析骨病変, pp172-181, 日本メディカルセンター, 1999
 
90) 冨永芳博 : 透析患者における至適PTH 濃度はいかにすべきか. 透析会誌 32 : 257-259, 1999
 
91) 冨永芳博 : 上皮小体 (副甲状腺) 細胞のモノクローナルな増殖機序. CLINCAL CALCIUM 9 : 71-74, 1999
 
92) 冨永芳博, 高木弘 : 副甲状腺摘除術のKnack & Pitfalls腎性副甲状腺機能亢進症の場合. 幕内雅敏 (監修) : Knack & Pitfalls内分泌外科の要点と盲点, pp140-143, 文光堂, 1999
 
93) 冨永芳博, 高木弘 : 術後管理と経過観察のKnack & Pitfalls腎性副甲状腺機能亢進症の場合. 幕内雅敏 (監修) : Knack & Pitfalls内分泌外科の要点と盲点, pp148-150, 文光堂, 1999
 
94) 冨永芳博 : どうなったら手術するのか? 太田和夫 (編) : 透析療法 Q&A, pp69-71, 医薬ジャーナル社, 1999
 
95) 冨永芳博 : 透析患者の上皮小体 (副甲状腺) 機能亢進症の治療とその選択. 丸茂文昭, 秋葉隆 (編) : 透析療法new wave, pp147-155, 中外医学社, 1999
 
96) 冨永芳博 : 副甲状腺 (上皮小体) の経皮的エタノール注入法. 中本雅彦, 佐中孜, 秋澤忠男 (編) : 透析療法辞典, pp293-294, 医学書院, 1999
 
97) 冨永芳博 : 副甲状腺 (上皮小体) 摘出術. 中本雅彦, 佐中孜, 秋澤忠男 (編) : 透析療法辞典, pp294-295, 医学書院, 1999
 
98) 冨永芳博 : 上皮小体機能亢進症の治療. 外科治療 81 : 40-46, 1999
Medical*Online
99) 冨永芳博, 貴田岡正史, 深川雅史, 秋澤忠男, 黒川清 : 選択的副甲状腺PEITに関するガイドライン (暫定案). 透析会誌 32 : 1099-1103, 1999
 
100) 冨永芳博 : 腎性上皮小体機能亢進症の病態と治療. 大阪透析研究会会誌 17 : 115-122, 1999
Medical*Online
101) 冨永芳博, 木全司 : 上皮小体 (副甲状腺) 機能亢進症. 臨床外科 54巻増刊号薬物療法マニュアル : 201-204, 1999
 
102) 冨永芳博 : 超音波ガイド下の腎性上皮小体機能亢進症治療-質疑応答. 日本医事新報 3946 : 110-111, 1999
 
103) 田中勇治, 冨永芳博 : 副甲状腺機能亢進症の診断のKnack & Pitfalls. 腎性副甲状腺機能亢進症の場合. 幕内雅敏 (監修) : Knack & Pitfalls内分泌外科の要点と盲点, pp132-133, 文光堂, 1999
 
104) 上村博, 志水麻実子, 岩佐充二, 安藤恒三郎, 幅俊人, 冨永芳博, 打田和治, 杉山成司 : 小児末期腎不全患者の血清カルニチン分画に与える生体腎移植の影響. 日本小児科学会雑誌 103 : 869-870, 1999
 
105) 田中勇治, 冨永芳博, 成瀬隆吉, 舟橋啓臣 : 上皮小体画像診断の進歩. 腎と骨代謝 13 : 311-316, 2000
 
106) 佐藤哲彦, 冨永芳博 : 腎性上皮小体機能亢進症手術適応の変遷. 腎と骨代謝 13 : 323-327, 2000
 
107) 日比八束, 冨永芳博 : 腎性上皮小体機能亢進症術式と問題点. 腎と骨代謝 13 : 329-335, 2000
 
108) 片山昭男, 稲垣浩子, 佐藤哲彦, 渡辺出, 幅俊人, 冨永芳博, 打田和治, 高木弘 : 透析患者における後天性嚢胞化萎縮腎 (ACDK) 合併腎細胞癌の検討. 腎と透析 48 別冊腎不全外科 2000 : 91-93, 2000
 
109) 深川雅史, 冨永芳博, 貴田岡正史, 秋澤忠男, 黒川清 : 選択的副甲状腺PEITに関するガイドライン 2000. 透析会誌 33 : 1343-1345, 2000
 
110) 冨永芳博 : 上皮小体 (副甲状腺) のモノクローナルな増殖機序. 腎と透析 48 : 479-483, 2000
 
111) 冨永芳博 : 上皮小体過形成の進展機序とその管理. 透析会誌 33 : 327-328, 2000
 
112) 冨永芳博 : 二次性上皮小体機能亢進症の病態とその治療. 乳腺, 甲状腺外科Practical Discussion 9 横浜カンファレンス 1999 : 75-85, 2000
 
113) 冨永芳博 : 腎移植と骨塩定量. 腎と骨代謝 13 : 233-239, 2000
 
114) 冨永芳博 : 甲状腺の腫瘍性疾患 多発性内分泌腫瘍症. 外科治療 82 (2000 増刊) 今日の腫瘍外科-最新の治療指針 : 1056-1061, 2000
 
115) 冨永芳博 : 二次性副甲状腺機能亢進症 外科的摘出術. 透析フロンティア 10 : 10-13, 2000
 
116) 冨永芳博 : 腎性上皮小体機能亢進症の病態と治療. 日本透析医会雑誌 15 : 231-239, 2000
 
117) 冨永芳博, 打田和治, 幅俊人, 片山昭男, 山田和弘, 日比八束, 佐藤哲彦, 高木弘 : 他施設で初回手術を受け, 持続性上皮小体機能亢進症または再発のため当院で再手術を施行した腎性上皮小体機能亢進症の検討. 腎と透析 48 別冊腎不全外科 2000 : 99-102, 2000
 
118) 冨永芳博 : 多発性内分泌腫瘍症. 外科治療 82 : 414-419, 2000
 
119) 冨永芳博 : 外科的治療. medicina別冊 21 : 2722-2726, 2001
 
120) 冨永芳博 : 腎性上皮小体機能亢進症に対する上皮小体摘出術. 腎と透析 50 別冊腎不全外科 2001 : 24-28, 2001
 
121) 寺町真理, 木全司, 荒川利治, 冨永芳博, 稲垣浩子, 佐藤哲彦, 渡辺出, 片山昭男, 幅俊人, 打田和治 : 二次性上皮小体機能亢進症手術後の服薬管理. 腎と透析 50 別冊腎不全外科 2001 : 119-121, 2001
 
122) 渡辺出, 稲垣浩子, 佐藤哲彦, 片山昭男, 幅俊人, 冨永芳博, 打田和治 : 超高齢者腎性上皮小体機能亢進症に対する治療法の検討. 腎と透析 50 別冊腎不全外科 2001 : 102-103, 2001
 
123) 冨永芳博 : 内分泌疾患 (甲状腺クリーゼなど). 臨牀透析 17 : 337-342, 2001
 
124) 冨永芳博 : 慢性腎不全におけるビタミンD療法の新しい展開 (6) 腎移植患者へのビタミンD療法. 臨牀透析 17 : 213-218, 2001
 
125) 冨永芳博 : 二次性副甲状腺 (上皮小体) 機能亢進症の外科療法. 医薬ジャーナル 37 : 182-185, 2001
 
126) 冨永芳博 : 腎性上皮小体 (副甲状腺) 機能亢進症の治療. ホルモンと臨床 49 : 639-646, 2001
 
127) 冨永芳博, 松岡慎, 佐藤哲彦, 後藤憲彦, 片山昭男, 幅俊人, 打田和治, 岩瀬仁一, 田嶋一喜 : 一期的に摘出し得た縦隔内上皮小体の存在した腎性上皮小体機能亢進症の1例. 臨牀透析 18 : 243-248, 2002
 
128) 冨永芳博 : 上皮小体 (副甲状腺) とリン. 腎と骨代謝 15 : 51-58, 2002
 
129) 冨永芳博 : 上皮小体 (副甲状腺) 摘出術. THE BONE 16 : 57-61, 2002
Medical*Online
130) 冨永芳博 : 上皮小体摘出術の効果. CLINICAL CALCIUM 12 : 71-75, 2002
 
131) 冨永芳博, 打田和治 : 腎移植後および上皮小体 (副甲状腺) 摘除後再発. 内分泌外科 19 : 251-256, 2002
 
132) 冨永芳博 : 感性. 腎と骨代謝 15 : 315-316, 2002
 
133) 冨永芳博 : 透析骨症治療の新しい展開. Bioclinica 17 : 76-80, 2002
 
134) 冨永芳博 : 上皮小体 (副甲状腺) 摘出術の適応と予後. 腎と透析 52 : 457-463, 2002
 
135) 冨永芳博 : 腎不全における上皮小体 (副甲状腺) 過形成の進展機構. 腎と骨代謝 15 : 117-128, 2002
 
136) 冨永芳博, 都築豊徳, 片山昭男, 打田和治, 幅俊人, 佐藤哲彦, 松岡慎, 後藤憲彦 : 肺に上皮小体転移巣を認めた腎性上皮小体機能亢進症の3例, 果たして上皮小体癌か? ホルモンと臨床 50 : 144-145, 2002
 
137) 冨永芳博 : 腎性上皮小体機能亢進症の手術適応. 外科治療 86 : 266-270, 2002
Medical*Online
138) 矢島愛治, 木村太一, 稲生綱政, 大坪修, 八木繁, 大坪公子, 小川由英, 秦野直, 冨永芳博 : PTXにより骨芽細胞面の増加が認められなかった1症例. 腎と透析 54 別冊腎不全外科 2003 : 91, 2003
 
139) 片山昭男, 冨永芳博, 後藤憲彦, 松岡慎, 佐藤哲彦, 幅俊人, 打田和治 : 腎性上皮小体機能亢進症に合併した縦隔腫瘍の2例. 腎と透析 54 別冊腎不全外科 2003 : 97-100, 2003
 
140) 冨永芳博 : 二次性上皮小体 (副甲状腺) 機能亢進症. 内分泌外科 20 : 55-58, 2003
 
141) 冨永芳博, 片山昭男, 松岡慎, 植木常雄, 後藤憲彦, 幅俊人, 打田和治 : 二次性上皮小体 (副甲状腺) 機能亢進症の周術期管理. 内分泌外科 20 : 379-389, 2003
 
142) 伊藤和子, 田中元子, 松下和孝, 冨永芳博 : 原発性副甲状腺機能亢進症の術後27年目に二次性副甲状腺機能亢進症を発症した血液透析患者の1例. 日本腎臓学会誌 45 : 706-712, 2003
 
143) 冨永芳博 : 移植した腎臓がだめになったらどうなるのですか. 透析ケア 2003年冬季増刊腎移植サポートブック, pp106-176, 2003
 
144) 佐藤哲彦, 冨永芳博 : 腎性上皮小体 (副甲状腺) 機能亢進症の手術適応. 日本内分泌外科学会 (編) : 内分泌外科標準手術アトラス改訂版, pp181-184, インターメルク, 2003
 
145) 冨永芳博 : 腎性上皮小体 (副甲状腺) 機能亢進症の手術. 日本内分泌外科学会 (編) : 内分泌外科標準手術アトラス改訂版, pp185-194, 2003
 
146) 冨永芳博 : 上皮小体 (副甲状腺) 機能亢進症がどこまで進行したら上皮小体摘出術が必要か? 中山書店, 2003
 
147) 冨永芳博 : 二次性上皮小体 (副甲状腺) 機能亢進症の外科療法と塩酸セベラマー. 医薬ジャーナル 39 : 147-149, 2003
 
148) 冨永芳博 : ROD患者のPTx治療. CLINICAL CALCIUM 13 : 100-103, 2003
 
149) 冨永芳博 : 上皮小体 (副甲状腺) 全摘出後自家移植術後のフォローアップ-再発防止のために-. 臨牀透析 19 : 79-89, 2003
 
150) 冨永芳博, 貴田岡正史, 秋澤忠男, 深川雅史, 弓田滋, 角田隆俊, 小岩文彦, 小野田教高, 黒川清 : わが国の腎性上皮小体 (副甲状腺) 機能亢進症に対する上皮小体摘出術の現況. 透析会誌 36 : 1361-1369, 2003
 
151) 冨永芳博 : 腎性副甲状腺機能亢進症. 内分泌外科 21 : 28-32, 2004
 
152) 松岡慎, 冨永芳博, 植木常雄, 後藤憲彦, 片山昭男, 幅俊人, 打田和治 : 下降不全上皮小体の重要性. 腎と透析 57 別冊腎不全外科 2004 : 70-72, 2004
 
153) 矢島愛治, 嘉手川豪心, 稲生綱政, 大坪修, 小川由英, 冨永芳博 : PTX前後の骨吸収および1-84PTH/large C-PTHについて. 腎と透析 57 別冊腎不全外科 2004 : 69, 2004
 
154) 矢島愛治, 小川由英, 稲生綱政, 大坪修, 八木繁, 冨永芳博 : 腎性上皮小体機能亢進症に対する上皮小体全摘除術の骨に対する治療効果とその限界. 内分泌外科 21 : 182-185, 2004
 
155) 冨永芳博 : PTH制御の新しいインターベンション. CLINICAL CALCIUM 14 : 51-55, 2004
 
156) 冨永芳博 : 腎不全患者に対する手術と輸血. 治療学 38 : 83-85, 2004
 
157) 冨永芳博 : 上皮小体 (副甲状腺) インターベンションと外科治療. 日本臨牀 62 : 574-577, 2004
Medical*Online
158) 冨永芳博, 松岡慎, 後藤憲彦, 片山昭男, 佐藤哲彦, 植木常雄, 幅俊人, 打田和治 : 副甲状腺 (上皮小体) 摘出術のタイミング (2) 外科医の立場から. 腎と骨代謝 17 : 277-283, 2004
 
159) 冨永芳博 : 上皮小体摘出術は高度腎性上皮小体 (副甲状腺) 機能亢進症の1st choice. 透析会誌 37 : 27-29, 2004
 
160) 冨永芳博 : 長期成績から見た腎性上皮小体機能亢進症に対するGold Standard. 内分泌外科 21 : 179-181, 2004
 
161) 冨永芳博 : PEITとPTx-その選択となる根拠は何か. 臨牀透析 20 : 952-960, 2004
 
162) 冨永芳博 : 重症二次性上皮小体 (副甲状腺) 機能亢進症. CLINICAL CALCIUM 14 : 106-111, 2004
 
163) 冨永芳博 : K/DOQIの腎機能障害における骨代謝障害ガイドラインについて考える. 臨牀透析 21 : 153-154, 2005
 
164) 冨永芳博 : カルシウム, リン代謝障害. 透析ケア 11 : 44-47, 2005
 
165) 冨永芳博 : 原発性上皮小体 (副甲状腺) 機能亢進症の手術適応. CLINICAL CALCIUM 15 : 79-84, 2005
 
166) 冨永芳博 : 副甲状腺をとってしまえば, 二次性副甲状腺機能亢進症は治る? 透析ケア 11 : 52-53, 2005
Medical*Online
167) 冨永芳博 : 副甲状腺 (上皮小体) 摘出術のコツと注意点. 手術 60 : 1959-1964, 2006
 
168) 冨永芳博, 松岡慎 : 続発性副甲状腺 (上皮小体) 機能亢進症の治療成績. 内分泌外科 23 別冊 : 24-28, 2006
 
169) 冨永芳博 : 二次性 (続発性, 腎性) 副甲状腺 (上皮小体) 機能亢進症. 内分泌外科 23 別冊 : 172-177, 2006
 
170) 冨永芳博 : 上皮小体 (副甲状腺) 摘出術の適応は? 秋澤忠男 (編) : 透析療法これは困ったぞ, どうしよう!, pp125-127, 中外医学社, 2006
 
171) 冨永芳博 : 副甲状腺摘出手術 (parathyroidectomy : PTx) に関するガイドライン. 腎と骨代謝 20 : 129-134, 2007
 
172) 冨永芳博 : 外科的治療透析患者の骨代謝・二次性副甲状腺機能亢進症. 日本透析医会 : 透析患者の合併症と対策 16, pp83-89, 2007
 
173) 冨永芳博 : 副甲状腺機能亢進症ガイドライン-副甲状腺インターベーション. 透析療法ネクスト VI 慢性透析療法とガイドライン, pp34-39, 医学図書出版, 2007
 
174) 冨永芳博 : 副甲状腺 (上皮小体) 摘出術と術後. 越川昭三 (監) : 症例に学ぶ透析療法, pp210-215, 中外医学社, 2007
 
175) 冨永芳博 : 副甲状腺の画像診断 (CT, MRI, シンチグラム). 透析患者の検査値の読み方改訂第2版, 日本メディカルセンター, pp386-389, 2007
 
176) 冨永芳博 : 二次性副甲状腺 (上皮小体) 機能亢進症の外科的治療. 慢性腎臓病に伴う骨ミネラル代謝異常 (CKD-MBD) , 医薬ジャーナル社, pp125-133, 2007
 
177) 冨永芳博 : 副甲状腺摘出術の適応と管理は? EBM透析療法, 中外医学社, pp350-353, 2007
 
178) 冨永芳博 : 一般手技による副甲状腺摘除手術のKnack & Pitfalls腎性副甲状腺機能亢進症の手術 (1) Wells法. 小原孝男 (編) : Knack & Pitfalls内分泌外科の要点と盲点第2版, 文光堂, pp240-243, 2007
 
179) 冨永芳博 : 副甲状腺機能亢進症診断のKnack & Pitfalls腎性副甲状腺機能亢進症. 小原孝男 (編) : Knack & Pitfalls内分泌外科の要点と盲点第2版, 文光堂, pp210-212, 2007
 
180) 冨永芳博 : 術後管理と経過観察のKnack & Pitfalls腎性副甲状腺機能亢進症. 小原孝男 (編) : Knack & Pitfalls内分泌外科の要点と盲点第2版, 文光堂, pp262-264, 2007
 
181) 冨永芳博 : 副甲状腺インターベンション. 日本透析医会雑誌 22 : 17-20, 2007
 
182) 冨永芳博 : 機能性副甲状腺 (上皮小体) 機能亢進症. 外科 69 : 1379-1385, 2007
 
183) 冨永芳博 : 副甲状腺摘出術の適応とその手技. 日本透析医会雑誌 22 : 433-434, 2007
 
184) 冨永芳博 : 周術期の観察点とサポート. 臨牀透析 23 : 1707-1712, 2007
 
185) 冨永芳博 : 機能性副甲状腺 (上皮小体) 機能亢進症. 外科 69 (11月増刊) 外科治療データブック : 1379-1385, 2007
 
186) 冨永芳博 : 副甲状腺 (上皮小体) 外科の最近の話題. 日本内分泌学会雑誌 84 (Suppl) : 11-14, 2008
 
187) 冨永芳博 : 副甲状腺 (上皮小体) 摘出術. 西沢良記 (編) : 最新透析医学, pp344-348, 医薬ジャーナル社, 2008
 
188) 松岡慎, 冨永芳博, 宇野暢晃, 佐藤哲彦 : 腎性副甲状腺機能亢進症PTx症例における1-84PTH測定の意義. 腎と骨代謝 21 : 233-237, 2008
 
189) 冨永芳博 : 副甲状腺インターベンションとシナカルセト塩酸塩. 腎と骨代謝 21 : 153-158, 2008
 
190) 冨永芳博 : 副甲状腺摘出術の適応とその手技. 日本透析医会雑誌 22 : 433-434, 2007
 
191) 冨永芳博 : 手術困難な副甲状腺 (上皮小体) 機能亢進症治療におけるcalcimimetics. CLINICAL CALCIUM 18 : 67-71, 2008
 
192) 冨永芳博 : 副甲状腺摘出術 (PTx) の実際. 副甲状腺インターベンション研究会 (編) : 副甲状腺インターベンションガイド, pp49-56, 文光堂, 2008
 
193) 冨永芳博 : シナカルセト塩酸塩は副甲状腺インターベンションをどう変えたか. Nephrology Frontier 7 : 41-45, 2008
 
194) 稲熊大城, 長屋啓, 原和弘, 立松美穂, 鈴木祥代, 倉田圭, 冨永芳博 : PTxを施行した透析導入前慢性腎不全の一例. 第19回日本腎性骨症研究会, メディカルレビュー社, pp57-59, 2008
 
195) 冨永芳博 : 二次性副甲状腺機能亢進症に対する副甲状腺摘出術の変遷-副甲状腺インターベンション研究会が果たしたこと. 第13回副甲状腺インターベンション研究会. 腎と骨代謝 22 : 89-90, 2008
 
196) 冨永芳博, 松岡慎 : 腎性副甲状腺機能亢進症に対する副甲状腺全摘・自家移植. 日本外科学会雑誌 2 : 96-100, 2009
 
197) 冨永芳博 : 副甲状腺摘出術後の輸液. 綜合臨牀 58 (増) 今すぐに役立つ輸液ガイドブック : 194-196, 2009
 
198) 冨永芳博 : 副甲状腺インターベンションの適応と今後の展望 CKD (慢性腎臓病) と骨. CLINICAL CALCIUM 19 : 77-82, 2009
 
199) 冨永芳博 : シナカルセト発売後の副甲状腺摘出術の適応について. 日本透析医会雑誌 24 : 129-133, 2009
 
200) 冨永芳博 : 副甲状腺摘出術 副甲状腺インターベンション. 深川雅史 (編) : CKD-MBDハンドブック, 日本メディカルセンター, pp147-153, 2009
 
201) 冨永芳博 : 国際内分泌外科学会に参加～オーストラリア, アデレード～. International Association of Endocrine Surgeons : IAES医療の広場 12 : 22-23, 2009
 
202) 冨永芳博, 松岡慎, 宇野暢晃, 橋本光弘, 阿知波雅人 : 血中インタクトPTH 測定試薬 アーキテクト・PTHの評価. 医学と薬学 61 : 921-925, 2009
Medical*Online
203) 中山ゆみ, 奥村百合子, 佐藤哲彦, 冨永芳博 : シャントの管理. 三木隆己, 白田久美子 (編) : ナースのための透析看護ハンドブック改訂3版, 医薬ジャーナル社, pp52-56, 2009
 
204) 矢島愛治, 稲葉雅章, 冨永芳博, 伊藤明美 : PTX後骨細胞性骨代謝回転と術後低骨折率の関連性について. 腎と透析 66 別冊腎不全外科 2009 : 62-63, 2009
 
205) 冨永芳博 : 原発性副甲状腺機能亢進症. CLINICAL CALCIUM 20 : 100-106, 2010
 
206) 冨永芳博 : 副甲状腺インターベンションの実際とその予後は? 深川雅史 (編) : EBM透析療法 2010-2011, 中外医学社, pp152-154, 2010
 
207) 冨永芳博 : 副甲状腺機能亢進症. 外科 72 (増) 必読セカンドオピニオン : 1452-1457, 2010
 
208) 冨永芳博 : 高カルシウム血症に対する薬物療法のトピックス. 内分泌外科 27 : 99-102, 2010
 
209) 冨永芳博 : 副甲状腺腫瘍の治療戦略；概論. 日本臨牀 69 (増) 内分泌腺腫瘍 : 440-444, 2011
 
210) 冨永芳博 : シナカルセト時代のPTx. 日本透析医会雑誌 26 : 203-208, 2011
 
211) 冨永芳博 : 副甲状腺機能亢進症. medicina 48 増刊号 : 482-484, 2011
 
212) 矢島愛治, 冨永芳博, 佐藤滋, 大坪茂, 稲葉雅章, 新田孝作, 伊藤明美 : 再発性腎性副甲状腺機能亢進症の1例. CLINICAL CALCIUM 21 : 95-100, 2011
 
213) 冨永芳博 : 原発性副甲状腺機能亢進症. 別冊日本臨牀 18 腎臓症候群 (第2版) 下 : 308-312, 2012
 
214) 冨永芳博 : 副甲状腺腫大の治療法をどう選択するか? -手術と内科的治療法および限界. 臨牀透析 28 (増) : 954-960, 2012
 
215) 冨永芳博 : 腎性副甲状腺機能亢進症に対する外科治療. 日本内分泌・甲状腺外科学会雑誌 29 : 21-25, 2012
 
216) 冨永芳博 : CKD-MBD 新ガイドラインの見極め 内科的治療の見極めと副甲状腺インターベンションの適応. 腎と骨代謝 4 : 351, 2012
 
217) 冨永芳博 : 腎と骨UPDATE～CKD-MBD概念の登場から5年を経て～二次性副甲状腺機能亢進症の外科治療. CLINICAL CALCIUM 22 : 1083-1088, 2012
 
218) 冨永芳博 : CKD・透析関連領域におけるガイドラインを日常診療にどう生かすか. CKD-MBDガイドライン 副甲状腺腫大の治療法をどう選択するか? 手術と内科的治療法および限界. 臨牀透析 28 (増) : 954-960, 2012
 
219) 松浦有希子, 稲熊大城, 板脇大輔, 隅智子, 中川星明, 岡田昭次, 高木茂樹, 新城響, 冨永芳博, 両角國男 : 透析液カルシウム濃度3.0 mEq/Lから2.75 mEq/Lへの変更は血清PTH濃度に影響しない. 透析会誌 45 : 873-880, 2012
 
220) 冨永芳博 : 二次性副甲状腺機能亢進症に対するPTx-わが国の現況と未来-. 日本透析医会雑誌 29 : 476-477, 2014
 
221) 山本貴之, 冨永芳博 : シナカルセトの適応拡大後の原発性副甲状腺機能亢進症, 副甲状腺癌に対する治療戦略. 日本内分泌・甲状腺外科学会雑誌 31 : 205-209, 2014
 
222) 山本貴之, 冨永芳博, 岡田学, 辻田誠, 平光高久, 後藤憲彦, 鳴海俊治, 渡井至彦 : 腎移植後遷延性副甲状腺機能亢進症に対する副甲状腺全摘前腕筋肉内自家移植術の意義. 日本臨床腎移植学会雑誌 2 : 180-183, 2014
Medical*Online
223) 成山真一, 冨永芳博, 澁谷浩二, 杉木雅彦, 野口哲也, 澁谷浩司, 西岡正登, 藤田嘉一, 依藤良一, 粕本博臣, 櫨木聡, 中西健 : 二次性副甲状腺機能亢進症を合併した透析患者の副甲状腺摘出術において術中intact PTHモニタリングを行った1例. 透析会誌 47 : 493-499, 2014
 
224) 山本貴之, 冨永芳博 : 透析患者の悪性腫瘍の危険因子と予防対策 (5) 甲状腺がんの早期発見. 臨牀透析 31 : 53-57, 2015
 
225) 冨永芳博 : 骨関節障害・CKD-MBDの概念を再考する IV 副甲状腺 (2) PTxの適応例-どんな症例でPTxが必要なのか. 臨牀透析 31 : 689-696, 2015
 
226) 冨永芳博 : Cinacalcet HCl導入前後のSHPTに対するPTxの変遷. 腎と透析 78 別冊腎不全外科 2015 : 6-12, 2015
 
227) 冨永芳博 : 二次性副甲状腺機能亢進症に対する外科的治療. 医薬ジャーナル 177-186, 2016
 
228) 冨永芳博 : 二次性副甲状腺機能亢進症の外科的治療. 腎臓内科・泌尿器科 3 : 482-487, 2016
 

書評

最近チェックした商品履歴

Loading...